# A role for genetic modifiers in tubulointerstitial kidney diseases.

## Author Names

Gary P Leggatt 1,2,4

Eleanor G Seaby 1

Kristin Veighey 1,4

Christine Gast 1,2

Rodney D Gilbert 1,3

Sarah Ennis 1

## Affiliations

1 – Human Genetics & Genomic Medicine, University of Southampton, Southampton, UK.

2 - Wessex Kidney Centre, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Southwick Hill Road, Cosham, Portsmouth, UK.

3 - Department of Paediatric Nephrology, Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, UK

4 - Renal Department, University Hospital Southampton, Southampton, UK

## Corresponding author

Gary P Leggatt

## Competing interests

None

## Abstract


With the increased availability of genomic sequencing technologies, the molecular bases for kidney diseases such as nephronophthisis, mitochondrially inherited, and autosomal dominant tubulointerstitial kidney diseases (ADTKD) has become increasingly apparent. These tubulointerstitial kidney diseases (TKD) are monogenic diseases of the tubulointerstitium and result in interstitial fibrosis and tubular atrophy (IF/TA). However, monogenic inheritance alone does not adequately explain the highly variable onset of kidney failure and extra-renal manifestations. Phenotypes vary considerably between individuals harbouring the same pathogenic variant in the same putative monogenic gene, even within families sharing common environmental factors. While the extreme end of the disease spectrum may have dramatic syndromic manifestations typically diagnosed in childhood, many patients present a more subtle phenotype with little to differentiate them from many other common forms of non-proteinuric chronic kidney disease (CKD). This review summarises the expanding repertoire of genes underpinning TKD and their known phenotypic manifestations. Furthermore, we collate the growing evidence for a role of modifier genes and discuss the extent to which these data bridge the historical gap between apparently rare monogenic TKD and polygenic non-proteinuric CKD (excluding polycystic kidney disease).

## Key points

* Tubulointerstitial kidney disease may present with a severe syndromic phenotype traditionally diagnosed in childhood, yet most TKD patients manifest a subtle phenotype with little to differentiate them from other common forms of non-proteinuric chronic kidney disease.
* Phenotypes may vary even within families that share the same putative monogenic gene variant and shared environmental factors.
* Common variants in monogenic TKD genes are also associated with chronic kidney disease at the population level.
* There is growing evidence for triallelic inheritance as well as for rare modifiers of severe effect, and common modifiers of moderate effect on patient phenotypes.

## Introduction

Tubulointerstitial kidney diseases (TKD) primarily involve the renal interstitium and tubular compartments. This typically results in tubulointerstitial fibrosis and tubular atrophy (IF/TA). The commonest TKDs include nephronophthisis, mitochondrially inherited, and autosomal dominant tubulointerstitial kidney diseases (ADTKD). TKD results from a growing number of single gene (monogenic) disorders. These are clinically characterised by a progressive decline in kidney function leading to chronic kidney disease (CKD) and end-stage kidney disease (ESKD). TKD typically results in non-proteinuric CKD and is clinically differentiated from glomerular diseases by a lack of glomerular proteinuria and haematuria. However, more significant proteinuria can occur in the late stages due to secondary glomerulosclerosis. There may be impaired urinary concentrating ability and sodium reabsorption resulting in polyuria and polydipsia. Extra-renal manifestations are highly variable (Table 1). In some instances, there may be renal cysts or structural abnormalities overlapping with polycystic kidney diseases (PKD) and congenital anomalies of the kidney and urinary tract (CAKUT), outside the scope of this review (Figure 1).



**Figure. 1 - Synonymous and umbrella terms in tubulointerstitial kidney disease (TKD)**

Initially 'lumped' under the term 'nephronophthisis-medullary cystic kidney disease' complex, the availability of genomic sequencing technologies has led to more detailed phenotypic and molecular characterisation. However, genetic and phenotypic nomenclature are now used interchangeably, creating the potential for confusion within multidisciplinary teams comprising geneticists and nephrologists. As patients have received genetic diagnoses, it has become clear that older terms such as familial juvenile hyperuricaemic nephropathy (FJHN) and medullary cystic kidney disease (MCKD) have needed updating (Figure 1 & Table 1). Multiple investigators have since demonstrated that neither tubular microcysts nor larger cysts are pathognomonic for these diseases, nor does the medulla appear to be the specific location for cysts when occasionally observed.73,153–155Some cases may be associated with hyperuricaemia and gout, but this is not pathognomonic and may be clinically silent in early disease.9,153 In an attempt to rectify this, the term ADTKD has been suggested by international guidelines, with the term ADTKD-NOS where the causal gene is unknown.100 Renal cysts and diabetes (RCAD) describes one of the potential manifestations of *HNF1B* variants that include isolated TKD and congenital anomalies of the kidney and urinary tract (CAKUT).

Nephronophthisis is characterised by IF/TA, tubular basement membrane abnormalities and cystic dilatation of the collecting duct.156 Extra-renal manifestations, including several eponymous syndromes (Table 1), are seen in approximately one-fifth of nephronophthisis cases and are collectively known as NPHP-related ciliopathies (NPHP-RC).13,103,157 A subset of ciliopathies recently named hepatorenal fibrocystic disease is characterised not only by renal IF/TA (with or without cysts) but also fibrosis and cystic dysgenesis of the liver and porto-biliary tract.158 Hepatorenal fibrocystic disease also includes autosomal recessive polycystic kidney disease (ARPKD) characterised by congenital hepatic fibrosis and cystic dilatation of the renal collecting duct and most commonly resulting from variants in the ciliary IPT domain-containing fibrocystin/polyductin (*PKHD1*).159 Autosomal dominant polycystic kidney disease (ADPKD) caused primarily by variants in polycystins 1 (*PKD1)* and 2 (PKD2) is also a ciliopathy; however, along with ARPKD, it falls outside the scope of this review, as cysts are the principal feature. Cystic dysplastic kidneys may occur alongside tubulointerstitial fibrosis in the lethal multisystem Meckel-Gruber syndrome. Cystic dysplasia or IF/TA may be present in Bardet-Biedl syndrome, short-rib thoracic dysplasia and COACH syndrome (Table 1).

Mitochondrial cytopathies result from inherited or sporadic variants in mitochondrial DNA (mtDNA) or nuclear DNA that affect mitochondrial function and may present with nephrotic syndrome, Fanconi syndrome, TKD alone or multisystem disorders*.*4,149,150 It has been suggested that the term mitochondrially inherited tubulointerstitial kidney disease (MITKD) is used to complement ADTKD.4

Most autosomal recessive TKD results from loss-of-function variants in genes encoding non-motile (primary) ciliary proteins. Cilia are organelles projecting from most mammalian cell types that communicate signals from the extracellular environment and other cells (Figure 4). Ciliopathies can result in isolated TKD, known as nephronophthisis (from the Greek for wasting of the nephron), as well as multisystem diseases (Figure 1 & Table 1). Over thirty genes are associated with nephronophthisis (Table 2); nephrocystin-1 (*NPHP1*) accounts for 20% of cases and other genes <3% each.1 ADTKD is caused by heterozygous variants in any one of at least five genes, including *UMOD*, *MUC1*, *HNF1B*, *REN* and *SEC61A1* (Table 2). The best studied is the *UMOD* gene encoding uromodulin, the most abundant protein in human urine.2 Recently, a phenotype with features of both TKD and PKD was attributed to variants in *DNAJB11*.3 Mitochondrially inherited TKD is also well described.4

Genetic TKD lies along a spectrum ranging from dramatic syndromic manifestations, typically diagnosed in childhood, to a more subtle phenotype difficult to distinguish from common forms of non-proteinuric CKD. Divergent phenotypes may be explained by variants of differing impact to gene functionality or mutated protein abundance. For example, homozygous variants in *TMEM231*, ranging from missense to null, are associated with diverse phenotypes, including Meckel Gruber syndrome (MKS), orofaciodigital syndrome (OFD) type 3 and Joubert Syndrome (JBTS) (Table 1).5–7 Furthermore, variants in constrained gene regions are more likely to impact protein function exemplified by heterozygous variants in the EGF2, EGF3 and D8C domains of *UMOD* resulting in earlier onset ESKD.8,9 However, patients with the same primary pathogenic variant often manifest significant differences in penetrance or expressivity.10 The wide variation in age of onset of CKD and extra-renal manifestations, including distinct syndromic disorders, is not adequately explained by our understanding of single-gene disorders alone. This brings into question the historical dichotomy of kidney diseases as either monogenic or polygenic (Figure 2).9,11–14 Whilst tissue mosaicism has been demonstrated in ADPKD and Alports, there is no evidence for this in TKD which suggests that mosaicism is not modifying variable expressivity.15

Monogenic forms result from rare variants with large effect sizes often manifesting severe disease (but may show variable penetrance). Whereas polygenic forms result from the cumulative effect of multiple common variants causing relatively milder disease. However, recent data suggests that monogenic disease risk may vary substantially due to polygenic background.16,17 Common variants in genes known to cause rare monogenic diseases are also associated with markers of CKD (e.g. UMOD, MUC1, *IQCB1* (*NPHP5*), *SDCCAG8* and *IFT172).*18–20 This is further supported by gene burden association tests on 450,000 UKBioBank whole exomes, available at genebass.org, showing that *UMOD*, *PKD2* and *SLC22A2* are most statistically associated with CKD.21

The concept of genetic modifiers was first introduced in 1941 by Haldane, but multiple definitions have since been suggested.22 Herein, modifier genes are defined as genes that alter the disease phenotype but are not required for the primary disease to be present. This is distinct from digenic or oligogenic inheritance, whereby two or more genes are essential for the manifestation of the primary disease phenotype.23 Genetic modifiers can affect the expression of another gene at multiple different organisational levels, including transcription, protein interactions, or the cellular and organ level.24 Terms such as epistasis, digenic/oligogenic inheritance or modifier genes are often used interchangeably to describe the effect of one gene/allele on the phenotypic outcome of another gene/allele.23 For triallelic inheritance (which can be synonymous with digenic or oligogenic inheritance), at least three mutated alleles are required to manifest a primary disease phenotype. Most typically this involves both alleles of one gene and at least one allele in a second gene; however, all three variants can occur on the same gene (Figure 2).25 Modifiers can be additive or suppressive and can affect penetrance, expressivity and dominance. This review collates the evidence for the role of modifier genes and oligogenic inheritance on the phenotypic spectrum of TKD and attempts to bridge the gap between apparently rare monogenic TKD and polygenic non-proteinuric CKD. Whilst epigenetic, environmental, and non-coding factors may also play a role, these are outside the scope of this review.

## The evidence for modifier genes

Modifier effects may be collectively common but are likely to be individually rare and heterogeneous and have therefore largely eluded discovery in underpowered studies. Most evidence comes from candidate gene or pathway approaches, with the more common variants likely to be tested first. Evidence for rare modifiers comes primarily from family case studies and are shown in Table 2.

### *NPHP1*

In 25% of isolated nephronophthisis cases, a large genetic deletion arises from homologous recombination of genetic repeats, resulting in deletion of 290kb and the entire *NPHP1* gene (83kb).26–28 Wide variation in age of ESKD (pre-puberty to seventh-decade) amongst patients homozygous for this deletion suggests modifier genes contribute to the variable phenotype.29,30 Hoefele *et al.* identified siblings with homozygous deletions of *NPHP1,* whereby both had nephronophthisis and retinitis pigmentosa. However, one sibling also carried a rare heterozygous variant in *NPHP4* and developed ESKD aged nine (eight years earlier than her sibling).31

In addition to marked differences in the age of onset, patients homozygous for *NPHP1* deletions can vary dramatically in their phenotype from isolated nephronophthisis with progressive CKD to Senior-Løken syndrome (SLSN), Bardet-Biedl syndrome (BBS), and mild forms of JBTS (Table 2).32–34

In a cohort of patients with nephronophthisis and neurological phenotypes consistent with Joubert syndrome (JBTS), half of those with variants in *NPHP1* also harboured a second variant, including heterozygous missense variants in *AHI1* and truncating variants in *CEP290*.29 In another study, the same hypomorphic variant in *AHI1* was associated with retinal disease in 153 patients with nephronophthisis, irrespective of the underlying genetic cause of nephronophthisis.35 Functional evidence for this modifier is seen in homozygous *Nphp1* knock out mice (Nphp-/-) crossed with heterozygous Ahi1 knockouts (Ahi1+/-) demonstrating more significant degenerative retinal lesions.35

### *NPHP3*

Autosomal recessive variants in *NPHP3* (Nephrocystin-3) were initially thought to cause adolescent or adult onset nephronophthisis.36 However, recent case reports describe much earlier onset of ESKD with some evidence for the role of genetic modifiers.37 In addition to pathogenic compound heterozygous variants in *NPHP3,* additional heterozygous frameshift or missense variants in *NPHP4* are described in a number of families associated with earlier disease including antenatal mortality.31,38

### *CEP290*

Autosomal recessive variants in *CEP290* (*NPHP6*) are implicated in an extensive range of syndromic clinical ciliopathies, including LCA, SLS, JBTS, BBS and MKS (Figure 3) and also isolated nephronophthisis.39–44 Variant type and location do not adequately explain the highly variable phenotype.45 A deep intronic *CEP290* variant (c.2991+1655A>G) resulting in aberrant splicing was identified in 16 (21%) of 76 unrelated patients with Leber congenital amaurosis (LCA). Despite altered splicing, a small amount of normally spliced protein was still present. This may explain the normal cerebellar and renal function in patients with LCA secondary to *CEP290* variants in a dosage-dependent mechanism, with complete loss of CEP290 protein function in more severe manifestations like JBTS.41 However, differential phenotypes could equally be influenced by tissue-specific variation in gene isoform expression due to alternative splicing.46,47 This has been previously observed for *WNK1*, where variants are alternatively expressed on different tissue-specific isoforms in the kidney and nervous system resulting in either hyperkalaemic hypertension or hereditary sensory and autonomic neuropathy type 2 respectively.48 Dose-dependent disease variants including alternative splicing and tissue-specific isoform expression in *CEP290* are unlikely to fully account for the observed phenotypic heterogeneity. A study screening patients with the same *CEP290* genotype but varied neurological severity revealed a novel heterozygous missense variant in *AHI1,* in a more severely affected patient.49 Furthermore, barttin CLCNK type accessory subunit beta (*BSND*), historically associated with Bartter syndrome type 4a, has been identified to modify the severity of cystic kidney disease and renal failure progression in JBTS caused by *CEP290* variants.50 Functional studies reveal a synergistic effect on the severity of phenotype with *CEP290* and knockout of *IQCB1* or *CC2D2A.*51,52 Other cilia components have also been shown to genetically or physically interact to modulate CEP290 phenotypes in mouse models (Figure 4).53

### *RGRIP1L*

Meckel-Gruber syndrome (MKS) and Bardet-Biedl syndrome (BBS) may be allelic forms of the same 'molecular spectrum', with hypomorphic variants in genes known to cause MKS (*MKS1*, *TMEM216* and *CEP290*) also associated with BBS.42 Biallelic truncating variants in *RPGRIP1L* (*NPHP8*) have been described to cause the more severe MKS, compared with missense variants in the same gene causing JBTS.54–59 In patients with a variety of syndromic ciliopathies attributed to variants in *NPHP3*, *IQCB1*, *CEP290* and *MKS1*, a common *RPGRIP1L* variant (p.Arg229Thr) (present in over 8% of South Asians and 3% of other populations) is significantly enriched in patients who also have retinitis pigmentosa.60,61

### *TTC21B*

Homozygous variants in tetratricopeptide repeat domain 21b *(TTC21B)* are associated with an array of different clinical entities including nephronophthisis, nephrotic range proteinuria, focal segmental glomerulosclerosis (FSGS) or global sclerosis.62 Amongst a cohort of patients with a 'ciliopathy', pathogenic alleles in *TTC21B* were identified in 38/753 (5%) patients, suggesting *TTC21B* variants commonly contribute to the overall variant burden. Seventeen patients carried heterozygous variants in at least one of 13 other genes (including *NPHP4, RPGRIP1L, TMEM216, CC2D2A, MKS1*) implicated in nephronophthisis or associated syndromes, suggesting modifying genetic activity.63

### *UMOD*

In addition to modifiers in other genes (*in*-*trans*), a phenotype may be altered by additional variation occurring in the same gene (*in*-*cis*) and on the same haplotype/chromosome as the primary disease variant (Figure 2) with exemplars seen in cystic fibrosis.64 *UMOD* variants contribute to both monogenic TKD and polygenic forms of CKD. Common risk variants for the development of CKD and hypertension in the promoter region of *UMOD* are thought to have risen in population frequency due to selective pressure from increased urinary uromodulin defending against urinary tract infections.19,65–69 A very high percentage of individuals have at least one risk variant that increases the quantity of uromodulin expressed (70 to 95%)*.*19,69 These variants are highly likely to co-occur in monogenic ADTKD-*UMOD* and may explain some of the extreme variation of progression to ESKD within families with the same pathogenic variant. A study of 147 families with monogenic ADTKD-*UMOD* identified underrepresentation of a protective allele (rs4293393 - associated with reduced uromodulin production) compared with large population databases. This protective allele was linked to monogenic *UMOD* variants in only 11.6% of affected families but was *in*-*cis* with 'wild-type' *UMOD* in 17%. This compares with an expected minor allele frequency of 18-20% from the Genome Aggregation Database (gnomAD).14 The authors postulate that this decreased protective allele frequency may be due to decreased expression of mutated uromodulin being less likely to receive a molecular diagnosis due to a milder clinical phenotype (with later development of ESKD).142 Rare cases of homozygous *UMOD* variants in two consanguineous families demonstrate a more severe phenotype than with heterozygous variants.70,71

### MUC1

ADTKD-MUC1 frequently results from the insertion of an additional cytosine into a variable number of tandem repeats (VNTRs), resulting in a frameshift variant in *MUC1*.61,72 The high guanosine/cytosine (GC) content of the VNTR region hinders short read sequencing, and therefore ADTKD-*MUC1* is probably underdiagnosed. The age of onset of ESKD ranges from 16 to 80 years.73 With an allele frequency of 42% (gnomAD genomes), a common variant in *MUC1* (rs4072037) is likely to coexist with monogenic forms of ADTKD-*MUC1*. It is an attractive genetic modifier candidate as it influences gene expression through alternative splice site mechanisms and is associated with declining kidney function in GWAS.18

### HNF1B

Heterozygous variants in *HNF1B,* or 17q12 microdeletions encompassing the *HNF1B* gene, are associated with large intra-familial variation in TKD (with and without cysts), maturity-onset diabetes of the young type 5 (MODY5), CAKUT and other organ involvement, including neuropsychiatric symptoms.74 Structural kidney abnormalities have been significantly associated with splice site variants, and MODY5 specifically with frameshift variants.75 However, an extensive retrospective analysis of 377 patients with *HNF1B* kidney disease revealed no correlation between the genetic variant and renal failure severity.76 Although the co-occurrence of neurodevelopmental disorders may be due to other genes in the microdeletion, more recent data suggest a role for epigenetic modifiers due to differential methylation patterns. 77,78 Evidence for the role of genetic modifiers is emerging with heterozygous *HNF1B* variants detected with heterozygous *PKD1* variants in a patient with early and more severe polycystic kidney disease.79 Another possible explanation for the wide phenotypic variability could be the influence of *HNF1B* as a transcription factor on the transcription of multiple other genes and, therefore, the specific variant burden in each of these downstream genes (Figure 4).

### Mitochondrial function

There are hundreds of mitochondrial DNA copies in each cell, and therefore mutated copies may exist with normal copies in a state known as heteroplasmy. Disease expression depends on the proportion of dysfunctional mitochondria and tissue distribution.80 Multiple organs may be affected, including the kidneys, skeletal muscle, and central nervous system. The range of kidney diseases associated with a m.3243A>G variant in the tRNALeu gene includes TKD and isolated tubulopathies, cystic kidney diseases, FSGS as well as syndromic forms including MELAS (myopathy, encephalopathy, lactic acidosis and stroke-like episodes) and maternally inherited diabetes and deafness (MIDD) syndrome.81,82 One family with MIDD syndrome also carried a second variant in tRNAlys, which was absent in 75 controls. Isolated TKD phenotypes also occur in cases where all copies of (homoplasmic) mitochondrial DNA are mutated.4

Secondary mitochondrial dysfunction also occurs in ADTKD-*UMOD*, resulting from the unfolded protein response and increased ER stress leading to a decrease in the number of mitochondria and associated proteins.83Any additional modifiers in the mitochondrial genome could affect the phenotype further (Figure 4).

* 1. **Evidence for oligogenic inheritance**

Bardet-Biedl Syndrome (BBS) is a multisystem disorder underpinned mainly by dysfunction of primary cilia (Table 1). Renal involvement in BBS is highly variable, including urine retention due to aberrant water trafficking, TKD, cystic dysplasia, hydronephrosis and CAKUT. Despite wide renal phenotypic heterogeneity, no genotype correlation has been identified.84 A multi-protein complex called the BBSome comprises protein subunits encoded by BBS genes. BBS was initially thought to be a monogenic recessive disorder, however deviation from the expected autosomal recessive inheritance pattern in many pedigrees suggested alternative inheritance models. Following the screening of a large cohort of BBS families for variants in *BBS2* and *MKKS,* triallelic inheritance was demonstrated in affected individuals from four pedigrees and revealed unaffected individuals from two pedigrees that carried two *BBS2* variants but none in *MKKS*.85 This is an example of digenic, triallelic inheritance (Figure 2). Since then, triallelic inheritance has been identified in other cohorts of BBS patients and other diseases.25,86–88 Beales *et al.* analysed 259 families and found evidence of triallelic inheritance and a homozygous missense variant of p.Met390Arg (the most frequent *BBS1* variant in European populations) in asymptomatic members of two families suggesting either incomplete penetrance or triallelic inheritance.86 Other studies have failed to identify triallelic inheritance in affected cases or have identified unaffected cases with biallelic inheritance. 87,8889–93 In other pedigrees, disease was identified in family members with rare double homozygous *BBS2* and BBS4 variants but not in triallelic first degree relatives.42,94

In a recent systematic secondary-variant burden analysis of patients with known biallelic variants in one of 17 BBS genes, researchers observed, in two independent cohorts, a non-random twofold enrichment of ultra-rare variants in other BBS genes compared with other recessive alleles and population controls.95 The suppression of 19 gene pairs in zebrafish revealed additive or suppressive effects and significant over-representation of secondary variants in BBS complex chaperonin genes.

Although most reports of BBS involve rare variants, functional evidence exists of a common modifier (1.4% of controls) in *CCDC28B* to disease severity.87 Given its population frequency, it may have been missed by traditional variant filtration approaches.

The relatively high incidence of renal developmental abnormalities and renal cell carcinoma in BBS patients' relatives may represent heterozygous carriers.96These findings suggest that triallelic inheritance results from modifier genes' action rather than oligogenic inheritance *per se* and that the degree of penetrance or expressivity is related to the cumulative effect of the variants.

## Discussion

The historical dichotomy of TKD as either monogenic or polygenic is overly simplistic. Evidence strongly suggests that TKD can be impacted by a diverse set of modifiers, as opposed to the simpler traditional model of one gene-one phenotype.25,85–94,96–98 The high prevalence of disease-specific modifier variants suggests their broad role in TKD and even CKD of all causes.20,60,87 Common risk variants may prove significant when present in the same monogenic disease gene; for example, when *in*-*cis* with primary pathogenic variants of *UMOD* and *MUC1.*18,19

Monogenic disease suffers from the 'Winner's curse' leading to a curtailing of genetic investigation once a single variant is identified. However, penetrance and expressivity of TKD are likely to be governed by the total variant burden, both within individual genes and across multiple gene pathways involved in the structure and function of the tubulointerstitium. The pleiotropic effects of pathogenic variants in *HNF1B* demonstrate the potential impact of gene networks.57,99 Multiple genetic 'hits' in these TKD genes are likely to contribute variably to the disease spectrum, from apparent monogenic to polygenic or multifactorial disease patterns. Here we describe severe rare modifiers and common moderate modifiers. However, it is essential to consider the role of multiple small-effect variants traditionally associated with polygenic diseases whose overall burden may be cumulatively large in some individuals, yet seldom identified due to weak association. Most studies focus on modifiers that result in more severe diseases, however patients with milder phenotypes, who are less likely to receive a molecular diagnosis, are equally likely to be subject to modifier genes. Only a minority of patients with TKD have overt extra-renal or syndromic manifestations, and even the renal phenotype may be subtle. With bland urinalysis or occasionally mild proteinuria and an association with renal cysts that is neither universal nor pathognomonic, TKD is difficult to differentiate from other non-proteinuric CKD. 100–102

Several barriers remain to understand the more complex genetics of TKD, including poor differentiation of TKD from other causes of CKD, inadequate phenotyping and nomenclature, and methodological challenges and biases in genetic analyses.

Recent evidence identifies relatively ‘mild’, adult-onset disease with recessive inheritance, and conversely, severe paediatric-onset disease resulting from dominant gene variants. For example autosomal recessive nephronophthisis due to *NPHP1*, the commonest genetic cause of paediatric ESKD, has recently been implicated in at least 0.5% of adult-onset ESKD.1,30,103 Conversely, autosomal dominant TKD resulting from variants in *HNF1B* and *REN* can cause severe disease in childhood.76,104 Molecular genetics has exposed the limitations of traditional clinical diagnostics, not only due to incomplete phenotyping but with phenocopies increasingly identified following molecular genetic testing.105,106 Attempts to increase diagnoses have led to multiple and sometimes misleading nomenclature that in some cases has been used to predefine limited molecular diagnoses such as the use of ADTKD-NOS (Not otherwise specified).

Multiple and sometimes misleading disease names predefine limited molecular diagnostics and reinforce bias (Figure 1). Attempts to increase diagnoses have led to terms such as autosomal dominant tubulointerstitial kidney disease (ADTKD) even before a molecular diagnosis has been made.100

Although massive datasets of normal variant distribution are now available, these allow comparison of the burden of rare variants on a population level but not on an individual level and often fail to provide contextual information for multiple variants. Additionally, extensive genomic datasets have historically been biased towards white European ancestry.

GWAS data implicate coding and non-coding variants with a variety of kidney traits, and these may prove important in the polygenic inheritance patterns of TKD. The challenge facing the research community is in the use of these data to identify variants that may contribute to the risk of disease progression or the emergence of TKD. One approach may be utilising resources that map expression quantitative trait loci (eQTLs) across multiple human tissues, aiding in the prioritisation of disease causing-genes.107

Genetic modifiers are methodologically challenging to detect and expensive to prove functionally. Classifying variants as benign, or pathogenic requires multiple types of evidence.108 The challenges to functional modelling of genetic variants in model systems for single variant disorders, scale exponentially with additional component alleles. The more alleles required to be modelled, the greater the experimental design's time, cost, and complexity.

Improved definition of the molecular mechanisms underlying TKD is required to inform prognosis and shift the emphasis from reactive therapies to secondary or primary prevention. Extensive prospective NGS analyses have the potential to unravel the genetic and phenotypic complexities of so-called monogenic kidney diseases, not least TKD.

Table 1 – The clinical entities and phenotypic descriptors constituting tubulointerstitial kidney diseases (TKD)

| Disease | Phenotype | Genes (Alias symbols in brackets) |
| --- | --- | --- |
| Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD-*UMOD*)  Also known as:  Uromodulin-Associated Kidney Disease (UAKD),  Familial Juvenile Hyperuricaemic Nephropathy (FJHN),  Medullary Cystic Kidney Disease type 2 (MCKD2) | Variably progressive CKD with IF/TA and minimal to no proteinuria  Early-onset hyperuricaemia/gout | *UMOD* |
| Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD-*MUC1*)  Also known as:  Mucin-1 Kidney Disease (MKD),  Medullary Cystic Kidney Disease type 1 (MCKD1) | Variably progressive CKD with IF/TA and minimal to no proteinuria | *MUC1* |
| Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD-*REN*)  Also known as:  Familial Juvenile Hyperuricaemic Nephropathy type 2 (FJHN2) | Variably progressive CKD with IF/TA and minimal to no proteinuria  Childhood/Adolescent onset: anaemia, hyperkalaemia, acidosis, progressive CKD and development of gout  Adult-onset: Slowly progressive CKD from the third decade, with or without gout | *REN* |
| Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD-*HNF1B*) | Associated features are variable and include:  Variably progressive CKD with IF/TA and minimal to no proteinuria  Congenital anomalies of kidney and urinary tract (CAKUT)  RCAD (Renal Cyst and Diabetes Syndrome)  Pancreatic hypoplasia  MODY5 (Maturity-Onset Diabetes mellitus of the Young type 5)  Urogenital malformations  Hypomagnesaemia  Cognitive impairment/Autism spectrum disorder (associated with 17q12 deletion) | *HNF1B* |
| Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD-*SEC61A1*) | Variably progressive CKD with IF/TA and minimal to no proteinuria  Small dysplastic kidneys  Congenital anaemia and neutropenia (with recurrent cutaneous abscesses)  Growth retardation | *SEC61A1* |
| Autosomal Dominant Tubulointerstitial Kidney Disease/Autosomal Dominant Polycystic Kidney Disease (ADTKD/ADPKD) overlap | Variably progressive CKD and hypertension  Non-enlarged cystic kidneys with interstitial fibrosis progressing to renal atrophy  Gout | *DNAJB11* |
| Nephronophthisis (NPHP) | Impaired urinary concentrating ability and sodium reabsorption (polyuria, polydipsia)  Normal or slightly small kidneys with increased echogenicity  Variably progressive CKD with IF/TA and minimal to no proteinuria  (Hepatic fibrosis, Situs inversus)  Sometimes categorised by median age of onset:   * Infantile (by 1 year of age) * Juvenile (by 13 years of age) * Adolescent (by 19 years of age) * Adult | *NPHP1, INVSƗ (NPHP2), NPHP3Ɨ, NPHP4Ɨ, IQCB1 (NPHP5), CEP290Ɨ (NPHP6), GLIS2 (NPHP7), RGRIP1LƗ (NPHP8), NEK8 (NPHP9), SDCCAG8 (NPHP10), TMEM67Ɨ (NPHP11), TTC21BƗ (NPHP12), WDR19 (NPHP13), ZNF423 (NPHP14), CEP164 (NPHP15), ANKS6 (NPHP16), IFT172 (NPHP17), CEP83 (NPHP18), DCDC2 (NPHP19), MAPKBP1 (NPHP20), IFT81, TRAF3IP1, ADMATS9, INPP5E, TMEM216, AHI1Ɨ, CC2D2A, TMEM237, TMEM138, IFT122, WDR35, IFT43.* |
| Senior-Løken syndrome (SLSN) | Nephronophthisis  Retinitis pigmentosa, Leber congenital amaurosis (LCA)  (Hepatic fibrosis, Situs inversus) | *NPHP1 (SLSN1), NPHP3Ɨ (SLSN3), NPHP4Ɨ (SLSN4), IQCB1 (SLSN5, NPHP5), CEP290Ɨ (SLSN6), SDCCAG8 (SLSN7), WDR19 (SLSN8), CEP164, TRAF3IP1 (SLSN9).* |
| Joubert syndrome (JBTS) | Nephronophthisis  Renal cystic dysplasia  Cerebellar vermis hypoplasia (characteristic 'Molar tooth' sign on MRI brain)  Ataxia, hypotonia  Hepatic fibrosis  Situs inversus  Polydactyly  Intellectual disability | *INPP5E (JBTS1), TMEM216 (JBTS2), AHI1Ɨ (JBTS3), NPHP1 (JBTS4), CEP290Ɨ (JBTS5), TMEM67Ɨ (JBTS6), RPGRIP1LƗ (JBTS7), ARL13B*\* *(JBTS8), CC2D2A (JBTS9), OFD1 (JBTS10), TTC21BƗ (JBTS11/NPHP12), KIF7*\* *(JBTS12), TCTN1*\* *(JBTS13), TMEM237 (JBTS14), CEP41*\* *(JBTS15), TMEM138 (JBTS16), CPLANE1*\* *(JBTS17), TCTN3 (JBTS18), ZNF423 (JBTS19), TMEM231 (JBTS20), CSPP1 (JBTS21), PDE6D (JBTS22), KIAA0586*\* *(JBTS23), TCTN2\* (JBTS24), CEP104*\* *(JBTS25), KIAA0556*\* *(JBTS26), B9D1 (JBTS27), MKS1 (JBTS28), TMEM107 (JBTS29), ARMC9*\* *(JBTS30), CEP120 (JBTS31), SUFU (JBTS32), PIBF1 (JBTS33), B9D2 (JBTS34), ARL3 (JBTS35), BSND*≠*.* |
| Meckel-Gruber syndrome (MKS) | Enlarged dysplastic cystic kidneys  Occipital encephalocele  Cleft palate  Hepatic fibrosis  Variable: polydactyly, skeletal dysplasia and situs inversus | *MKS1, TMEM216 (MKS2), TMEM67Ɨ (MKS3), CEP290Ɨ (MKS4), RPGRIP1LƗ (MKS5), CC2D2A (MKS6), NPHP3Ɨ (MKS7), TCTN2\* (MKS8), B9D1 (MKS9), B9D2 (MKS10), TMEM231 (MKS11), KIF14 (MKS12), TMEM107 (MKS13), CSPP1, TXNDC15, TMEM237, CPLANE1\*, CEP55.* |
| COACH syndrome | Nephronophthisis  Renal cystic dysplasia  Cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma and hepatic fibrosis | *TMEM67Ɨ, CC2D2A, RPGRIP1LƗ.* |
| Short-rib thoracic dysplasia (SRTD) with or without polydactyly  Also known as:  Asphyxiating thoracic dystrophy  Jeune syndrome | Nephronophthisis  Renal cystic dysplasia  Constricted thoracic cage  Short ribs  Shortened tubular bones  Variable: Multiorgan involvement, polydactyly, hepatic fibrosis, intellectual disability | *CEP120, CSPP1, DYNC2H1, DYNC2LI1, IFT140, IFT172, IFT43, IFT52, IFT80, IFT81, INTU, KIAA0586*\**, NEK1, TCTEX1D2, TTC21BƗ, WDR19, WDR34, WDR35, WDR60.* |
| Cranio-ectodermal dysplasia (CED) | Nephronophthisis  Skeletal abnormalities  Craniosynostosis (premature closure of cranial sutures)  Ectodermal abnormalities | *IFT122 (CED1), WDR35 (CED2), IFT43 (CED3), WDR19 (NPHP13, CED4).* |
| Bardet-Biedl syndrome (BBS) | Nephronophthisis  Renal cystic dysplasia  Focal Segmental glomerulosclerosis (FSGS)  Rod-cone dystrophy  Polydactyly  Obesity  Genital malformations  Intellectual disability | *BBS1, BBS2, ARL6 (BBS3), BBS4, BBS5, MKKS (BBS6), BBS7, TTC8 (BBS8), BBS9, BBS10, TRIM32 (BBS11), BBS12, MKS1Ɨ (BBS13), CEP290Ɨ (BBS14), WDPCPƗ (BBS15), SDCCAG8 (BBS16), LZTFL1 (BBS17), BBIP1 (BBS18), IFT27 (BBS19), IFT74 (BBS20), C8ORF37 (BBS21), IFT172, NPHP1, CCDC28B*≠*, TMEM67Ɨ.* |
| Alström syndrome | Progressive CKD with IF/TA  Cone-rod dystrophy  Obesity  Progressive sensorineural hearing loss  Cardiomyopathy  Type 2 diabetes | *ALMS1* |
| Karyomegalic interstitial nephritis (KIN) | Variably progressive CKD  IF/TA with enlarged and atypical tubular epithelial cell nuclei | *FAN1* |
| Renal tubular dysgenesis | Fetal anuria and perinatal death from pulmonary hypoplasia and oligohydramnios (Potters syndrome) | *REN, AGT, AGTR1, ACE.* |
| Mitochondrial inherited tubulointerstitial kidney disease (MITKD) | Isolated variably progressive CKD with bland urinalysis and IF/TA and no Fanconi syndrome or extra-renal manifestations  Tubulopathy, including Fanconi syndrome  FSGS, Glomerulocystic kidney disease  A multisystem disease of muscles and neurological system but can include other organ systems:  Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS)  Maternally inherited diabetes and deafness (MIDD) syndrome  Mitochondrial DNA deletion syndromes | *MTTF (*mt-tRNAPhe*), ML-TL1* (mt-tRNALeu)*,* Mitochondrial DNA deletions*.* |
| \*No convincing evidence of renal disease, Ɨ'Causative' and disease modifier, ≠ Disease modifier only | | |

**Table 2 - Monogenic causes of TKD and evidence of modifier genes**

| HGNC gene symbol | HGNC approved gene name | Diagnosis | Gene Location | Assumed inheritance pattern | Oligogenic/Modifier genes | |
| --- | --- | --- | --- | --- | --- | --- |
| Nephronophthisis | | | | | | |
| *NPHP1*120,121 | Nephrocystin 1 | Nephronophthisis 1  Senior-Løken syndrome 1  Joubert syndrome 4  Bardet-Biedl syndrome | 2q13 | AR | Homozygous *NPHP1* is possibly modified by heterozygous *NPHP4* with early-onset ESKD.31  Heterozygous *AHI1* variants are enriched in patients with homozygous *NPHP1* and neurological symptoms.29 | |
| *NPHP3*36 | Nephrocystin 3 | Nephronophthisis 3  Senior-Løken syndrome 3  Meckel-Gruber syndrome 7  Renal-hepatic-pancreatic dysplasia 1  Situs inversus  Hepatic fibrosis | 3q22.1 | AR | Possible digenic inheritance with *INVS.* 31  A heterozygous *NPHP4* variant may modify compound heterozygous *NPHP3* with early-onset ESKD and hepatic fibrosis.31,38  In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60 | |
| *CEP290*39,40 | Centrosomal protein 290 | Nephronophthisis 6  Senior-Løken syndrome 6  Joubert syndrome  Bardet-Biedl syndrome 14  Hepatic fibrosis  Meckel-Gruber syndrome 4 | 12q21.32 | AR | Heterozygous pathogenic variants are present in several cases of homozygous *NPHP1* but with no evidence of modifier effect on phenotype.29  There is a more severe neurological disease in a patient with biallelic *CEP290* variants and a heterozygous *AHI1*.49  Possible triallelic disease with heterozygous *TMEM67* and homozygous *CEP290* variants in BBS.42  In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60  A variant in barttin CLCNK type accessory subunit beta *(BSND)* I significantly associated with kidney disease severity in patients with CEP290 variants.50 | |
| *RPGRIP1L*55 | Retinitis pigmentosa GTPase regulator-interacting protein 1 like protein | Nephronophthisis 8  Joubert syndrome 7  COACH syndrome  Hepatic fibrosis  Meckel-Gruber syndrome 5 | 16q12.2 | AR | In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60 | |
| *TTC21B*63 | Tetratricopeptide repeat domain 21B | Nephronophthisis 12  Joubert syndrome 11  Short-rib thoracic dysplasia  Focal segmental glomerulosclerosis (FSGS) | 2q24.3 | AR, AD | Both causal and a possible modifier of multiple ciliopathy genes including *BBS1, BBS2, BBS4, MKKS, BBS7, BBS10, BBS12, NPHP4, CC2D2A* and *TMEM216*.63  *TTC21B* is a possible modifier in patients with FSGS and collagen type 4 gene variants (*COL4A3* and *COL4A5).*62 | |
| *INVS*122 | Inversin | Nephronophthisis 2  Situs inversus  Hepatic fibrosis | 9q31.1 | AR | Possible digenic inheritance with *NPHP3.*31 | |
| *NPHP4*123,124 | Nephrocystin 4 | Nephronophthisis 4  Senior-Løken syndrome 4  Hepatic fibrosis | 1p36.1 | AR | Homozygous *NPHP1* possibly modified by heterozygous *NPHP4* with early-onset ESKD.31  Compound heterozygous *NPHP3* modified by heterozygous *NPHP4* variant with early-onset ESKD and hepatic fibrosis.31,38  *TTC21B* contributes possible modifier alleles to *NPHP4*.63 | |
| *IQCB1*125 | IQ motif containing B1 | Nephronophthisis 5  Senior-Løken syndrome 5 | 3q13.33 | AR | Common variants are associated with elevated creatine in association studies.20  In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60 | |
| *GLIS2*126 | GLIS family zinc finger 2 | Nephronophthisis 7 | 16p13.3 | AR |  | |
| *NEK8*127 | NIMA related kinase 8 | Nephronophthisis 9  Rena-hepatic-pancreatic-dysplasia 2  Hepatic fibrosis | 17q11.2 | AR |  | |
| *SDCCAG8*128 | Serologically defined colon cancer antigen 8 | Nephronophthisis 10  Senior-Løken syndrome 7  Bardet-Biedl syndrome 16  Intellectual disability | 1q43-q44 | AR | Common variants in *SDCCAG8* are associated with elevated creatine in association studies.20 | |
| *TMEM67*129 | Transmembrane protein 67 | Nephronophthisis 11  Joubert syndrome 6  Meckel-Gruber syndrome 3  COACH syndrome  Hepatic fibrosis | 8q22.1 | AR | Possible triallelic disease in BBS contributing heterozygous *TMEM67* variants to homozygous truncating variants in *CEP290*.42  Possible triallelic disease contributing heterozygous *TMEM67* and homozygous *BBS9* variants in BBS.42 | |
| *WDR19*130 | WD repeat domain 19 | Nephronophthisis 13  Senior-Løken syndrome 8  Cranioectodermal dysplasia 4  Short-rib thoracic dysplasia 5  Hepatic fibrosis | 4p14 | AR |  | |
| *ZNF423*131 | Zinc finger protein 423 | Nephronophthisis 14  Joubert syndrome 19  Situs inversus | 16q12.1 | AR, AD |  | |
| *CEP164*131 | Centrosomal protein 164 | Nephronophthisis 15  Senior-Løken syndrome  Meckel-Gruber syndrome  Joubert syndrome  Hepatic fibrosis | 11q23.3 | AR |  | |
| *ANKS6*132 | Ankyrin repeat and sterile alpha motif domain containing 6 | Nephronophthisis 16  Situs inversus  Hepatic fibrosis | 9q22.33 | AR |  | |
| *IFT172*133 | Intraflagellar transport 172 | Nephronophthisis 17  Bardet-Biedl syndrome  Short-rib thoracic dysplasia 10  Hepatic fibrosis | 2p23.3 | AR | Common variants in *IFT172* are associated with elevated creatine in association studies.20 | |
| *CEP83*134 | Centrosomal protein 83 | Nephronophthisis 18  Intellectual disability  Hepatic fibrosis | 12q22 | AR |  | |
| *DCDC2*135 | Doublecortin domain containing 2 | Nephronophthisis 19  Hepatic fibrosis  Non-syndromic recessive deafness | 6q22.3 | AR |  | |
| *MAPKBP1*136 | Mitogen-activated protein kinase binding protein 1 | Nephronophthisis 20 | 15q15.1 | AR |  | |
| *IFT81*137 | Intraflagellar transport 81 | Nephronophthisis  Short-rib thoracic dysplasia 19 | 12q24.11 | AR |  | |
| *TRAF3IP1*138 | TRAF3 interacting protein 1 | Nephronophthisis  Senior-Løken syndrome 9  Intellectual disability | 2q37.3 | AR |  | |
| *ADAMTS9*139 | ADAM metallopeptidase with thrombospondin type 1 motif 9 | Nephronophthisis | 3p14.1 | AR |  | |
| *INPP5E*140 | Inositol polyphosphate-5-phosphatase E | Nephronophthisis  Joubert syndrome 1  Hepatic fibrosis  Intellectual disability | 9q34.3 | AR |  | |
| *TMEM216*141 | Transmembrane protein 216 | Nephronophthisis  Joubert syndrome 2  Meckel-Gruber syndrome 2  Orofaciodigital syndrome  Intellectual disability | 11q13.1 | AR | *TTC21B* contributes possible modifier alleles.63 | |
| *AHI1*142 | Abelson helper integration site 1 (Jouberin) | Nephronophthisis  Joubert syndrome 3  Intellectual disability | 6q23.3 | AR | Heterozygous *AHI1* variants are enriched in patients with homozygous *NPHP1* and neurological symptoms.29  More severe neurological disease in a patient with biallelic *CEP290* variants and a heterozygous *AHI1*.49  Heterozygous *AHI1* variants are associated with retinal disease irrespective of the underlying biallelic cause of Nephronophthisis.35 | |
| *CC2D2A*51 | Coiled-coil and C2 domain-containing 2A | Nephronophthisis (possible mild)  Meckel-Gruber syndrome 6  Joubert syndrome 9  COACH syndrome 2  Hepatic fibrosis  Intellectual disability | 4p15.32 | AR | *TTC21B* contributes possible modifier alleles.63 | |
| *TMEM237*143 | Transmembrane protein 237 | Nephronophthisis  Joubert syndrome 14  Meckel-Gruber syndrome | 2q33.1 | AR |  | |
| *TMEM138*144 | Transmembrane protein 138 | Nephronophthisis (rare)  Joubert syndrome 16  Orofaciodigital syndrome | 11q12.2 | AR |  | |
| *TMEM231*7 | Transmembrane protein 231 | Cystic kidneys  Joubert syndrome 20  Orofaciodigital syndrome 3  Meckel-Gruber syndrome 11 | 16q23.1 | AR |  | |
| IFT122145 | Intraflagellar transport 122 | Nephronophthisis  Cranioectodermal dysplasia 1  Hepatic fibrosis | 3q21.3-q22.1 | AR |  | |
| WDR35146 | WD repeat domain 35 | Nephronophthisis  Cranioectodermal dysplasia 2  Short-rib thoracic dysplasia 7  Hepatic fibrosis | 2p24.1 | AR |  | |
| IFT43147 | intraflagellar transport 43 | Nephronophthisis  Cranioectodermal dysplasia 3  Short-rib thoracic dysplasia 18  Hepatic fibrosis | 14q24.3 | AR |  | |
| *ALMS1*148 | ALMS1 centrosome and basal body associated protein | Alström syndrome | 2p13.1 | AR |  | |
| Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) | | | | | | |
| *UMOD*2 | Uromodulin | ADTKD-*UMOD* | 16p12.3 | AD | Common promoter variants are associated with the risk of CKD and hypertension.19,65–69,109,110  Biallelic variants are more severe.111 | |
| *MUC1*112 | Mucin 1, cell surface-associated | ADTKD-*MUC1* | 1q22 | AD | Common splice site variant increases the risk of CKD18 | |
| *HNF1B*115 | HNF1 homeobox B | ADTKD-*HNF1B* | 17q12 | AD | *HNF1B* has a role in transcriptional activation of *UMOD*, *PKHD1* and *PKD2* genes.116 | |
| *REN*113 | Renin | ADTKD-*REN*  Renal tubular dysgenesis | 1q32.1 | AD  AR | Biallelic variants cause a more severe phenotype resulting in renal tubular dysgenesis114 | |
| *SEC61A1*117 | SEC61 translocon alpha 1 subunit | ADTKD-*SEC61A1* | 3q21.3 | AD |  | |
| *DNAJB11*3 | DnaJ heat shock protein family (Hsp40) member B11 | ADTKD/ADPKD 'hybrid'  Ivermark II syndrome - Renal-hepatic-pancreatic dysplasia (RHPD) | 3q27.3 | AD  AR | Biallelic variants cause a more severe phenotype with a fetal disease, including enlarged cystic kidneys, dilation and proliferation of pancreatic duct cells, and liver ductal plate malformation.118 | |
| Mitochondrial disorders | | | | | | |
| *MT-TF*4 | Mitochondrially encoded tRNA-Phe (UUU/C) | Mitochondrially inherited tubulointerstitial kidney disease (MITKD) | Mitochondria | Mitochondria |  | |
| *MT-TL1*119 | Mitochondrially encoded tRNA-Leu (UUA/G) 1 | Mitochondrial Encephalopathy, Lactic acidosis, and Stroke-like episodes (MELAS)  Maternally inherited diabetes and deafness (MIDD) Syndromes | Mitochondria | Mitochondria | A possible modifying variant in tRNAlys in a family with m.3243A>G and MIDD rather than MELAS, the tRNAlys variant was absent in 75 controls.82 | |
| Renal tubular dysgenesis | | | | | | |
| *AGT*114 | Angiotensinogen | Renal tubular dysgenesis | 1q42.2 | AR |  | |
| *AGTR1*114 | Angiotensin II receptor type 1 | Renal tubular dysgenesis | 3q24 | AR |  | |
| *ACE*114 | Angiotensin I converting enzyme | Renal tubular dysgenesis | 17q23.3 | AR |  | |
| Other | | | | | | |
| *XPNPEP3*149 | X-prolyl aminopeptidase 3 | Nephronophthisis-like nephropathy 1 (NPHPL1) | 22q13.2 | AR |  | |
| *GATM*150 | Glycine amidinotransferase | Fanconi syndrome and IFTA | 15q21.1 | AD |  | |
| *SLC41A1*151 | Solute carrier family 41 member 1 | Nephronophthisis-like nephropathy | 1q32.1 | AR |  | |
| *FAN1*152 | FANCD2 and FANCI associated nuclease 1 | Karyomegalic interstitial nephritis | 15q13.3 | AR |  | |
| AD – autosomal dominant, ADTKD - Autosomal dominant tubulointerstitial kidney disease, ADPKD - Autosomal dominant polycystic kidney disease, AR – Autosomal recessive, COACH syndrome - Cerebellar vermis hypo/aplasia, oligophrenia, congenital ataxia, ocular coloboma, and hepatic fibrosis, ESKD – End-stage kidney disease, FSGS - Focal segmental glomerulosclerosis, MITKD - Mitochondrial inherited tubulointerstitial kidney disease. | | | | | | |
| HGNC gene symbol | | | | | | HGNC approved gene name | | Diagnosis | Gene Location | Assumed inheritance pattern | Oligogenic/Modifier genes |
| Nephronophthisis | | | | | | | | | | | |
| *NPHP1*120,121 | | | | | | Nephrocystin 1 | | Nephronophthisis 1  Senior-Løken syndrome 1  Joubert syndrome 4  Bardet-Biedl syndrome | 2q13 | AR | Homozygous *NPHP1* is possibly modified by heterozygous *NPHP4* with early-onset ESKD.31  Heterozygous *AHI1* variants are enriched in patients with homozygous *NPHP1* and neurological symptoms.29 |
| *NPHP3*36 | | | | | | Nephrocystin 3 | | Nephronophthisis 3  Senior-Løken syndrome 3  Meckel-Gruber syndrome 7  Renal-hepatic-pancreatic dysplasia 1  Situs inversus  Hepatic fibrosis | 3q22.1 | AR | Possible digenic inheritance with *INVS.* 31  A heterozygous *NPHP4* variant may modify compound heterozygous *NPHP3* with early-onset ESKD and hepatic fibrosis.31,38  In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60 |
| *CEP290*39,40 | | | | | | Centrosomal protein 290 | | Nephronophthisis 6  Senior-Løken syndrome 6  Joubert syndrome  Bardet-Biedl syndrome 14  Hepatic fibrosis  Meckel-Gruber syndrome 4 | 12q21.32 | AR | Heterozygous pathogenic variants are present in several cases of homozygous *NPHP1* but with no evidence of modifier effect on phenotype.29  There is a more severe neurological disease in a patient with biallelic *CEP290* variants and a heterozygous *AHI1*.49  Possible triallelic disease with heterozygous *TMEM67* and homozygous *CEP290* variants in BBS.42  In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60  A variant in barttin CLCNK type accessory subunit beta *(BSND)* I significantly associated with kidney disease severity in patients with CEP290 variants.50 |
| *RPGRIP1L*55 | | | | | | Retinitis pigmentosa GTPase regulator-interacting protein 1 like protein | | Nephronophthisis 8  Joubert syndrome 7  COACH syndrome  Hepatic fibrosis  Meckel-Gruber syndrome 5 | 16q12.2 | AR | In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60 |
| *TTC21B*63 | | | | | | Tetratricopeptide repeat domain 21B | | Nephronophthisis 12  Joubert syndrome 11  Short-rib thoracic dysplasia  Focal segmental glomerulosclerosis (FSGS) | 2q24.3 | AR, AD | Both causal and a possible modifier of multiple ciliopathy genes including *BBS1, BBS2, BBS4, MKKS, BBS7, BBS10, BBS12, NPHP4, CC2D2A* and *TMEM216*.63  *TTC21B* is a possible modifier in patients with FSGS and collagen type 4 gene variants (*COL4A3* and *COL4A5).*62 |
| *INVS*122 | | | | | | Inversin | | Nephronophthisis 2  Situs inversus  Hepatic fibrosis | 9q31.1 | AR | Possible digenic inheritance with *NPHP3.*31 |
| *NPHP4*123,124 | | | | | | Nephrocystin 4 | | Nephronophthisis 4  Senior-Løken syndrome 4  Hepatic fibrosis | 1p36.1 | AR | Homozygous *NPHP1* possibly modified by heterozygous *NPHP4* with early-onset ESKD.31  Compound heterozygous *NPHP3* modified by heterozygous *NPHP4* variant with early-onset ESKD and hepatic fibrosis.31,38  *TTC21B* contributes possible modifier alleles to *NPHP4*.63 |
| *IQCB1*125 | | | | | | IQ motif containing B1 | | Nephronophthisis 5  Senior-Løken syndrome 5 | 3q13.33 | AR | Common variants are associated with elevated creatine in association studies.20  In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60 |
| *GLIS2*126 | | | | | | GLIS family zinc finger 2 | | Nephronophthisis 7 | 16p13.3 | AR |  |
| *NEK8*127 | | | | | | NIMA related kinase 8 | | Nephronophthisis 9  Rena-hepatic-pancreatic-dysplasia 2  Hepatic fibrosis | 17q11.2 | AR |  |
| *SDCCAG8*128 | | | | | | Serologically defined colon cancer antigen 8 | | Nephronophthisis 10  Senior-Løken syndrome 7  Bardet-Biedl syndrome 16  Intellectual disability | 1q43-q44 | AR | Common variants in *SDCCAG8* are associated with elevated creatine in association studies.20 |
| *TMEM67*129 | | | | | | Transmembrane protein 67 | | Nephronophthisis 11  Joubert syndrome 6  Meckel-Gruber syndrome 3  COACH syndrome  Hepatic fibrosis | 8q22.1 | AR | Possible triallelic disease in BBS contributing heterozygous *TMEM67* variants to homozygous truncating variants in *CEP290*.42  Possible triallelic disease contributing heterozygous *TMEM67* and homozygous *BBS9* variants in BBS.42 |
| *WDR19*130 | | | | | | WD repeat domain 19 | | Nephronophthisis 13  Senior-Løken syndrome 8  Cranioectodermal dysplasia 4  Short-rib thoracic dysplasia 5  Hepatic fibrosis | 4p14 | AR |  |
| *ZNF423*131 | | | | | | Zinc finger protein 423 | | Nephronophthisis 14  Joubert syndrome 19  Situs inversus | 16q12.1 | AR, AD |  |
| *CEP164*131 | | | | | | Centrosomal protein 164 | | Nephronophthisis 15  Senior-Løken syndrome  Meckel-Gruber syndrome  Joubert syndrome  Hepatic fibrosis | 11q23.3 | AR |  |
| *ANKS6*132 | | | | | | Ankyrin repeat and sterile alpha motif domain containing 6 | | Nephronophthisis 16  Situs inversus  Hepatic fibrosis | 9q22.33 | AR |  |
| *IFT172*133 | | | | | | Intraflagellar transport 172 | | Nephronophthisis 17  Bardet-Biedl syndrome  Short-rib thoracic dysplasia 10  Hepatic fibrosis | 2p23.3 | AR | Common variants in *IFT172* are associated with elevated creatine in association studies.20 |
| *CEP83*134 | | | | | | Centrosomal protein 83 | | Nephronophthisis 18  Intellectual disability  Hepatic fibrosis | 12q22 | AR |  |
| *DCDC2*135 | | | | | | Doublecortin domain containing 2 | | Nephronophthisis 19  Hepatic fibrosis  Non-syndromic recessive deafness | 6q22.3 | AR |  |
| *MAPKBP1*136 | | | | | | Mitogen-activated protein kinase binding protein 1 | | Nephronophthisis 20 | 15q15.1 | AR |  |
| *IFT81*137 | | | | | | Intraflagellar transport 81 | | Nephronophthisis  Short-rib thoracic dysplasia 19 | 12q24.11 | AR |  |
| *TRAF3IP1*138 | | | | | | TRAF3 interacting protein 1 | | Nephronophthisis  Senior-Løken syndrome 9  Intellectual disability | 2q37.3 | AR |  |
| *ADAMTS9*139 | | | | | | ADAM metallopeptidase with thrombospondin type 1 motif 9 | | Nephronophthisis | 3p14.1 | AR |  |
| *INPP5E*140 | | | | | | Inositol polyphosphate-5-phosphatase E | | Nephronophthisis  Joubert syndrome 1  Hepatic fibrosis  Intellectual disability | 9q34.3 | AR |  |
| *TMEM216*141 | | | | | | Transmembrane protein 216 | | Nephronophthisis  Joubert syndrome 2  Meckel-Gruber syndrome 2  Orofaciodigital syndrome  Intellectual disability | 11q13.1 | AR | *TTC21B* contributes possible modifier alleles.63 |
| *AHI1*142 | | | | | | Abelson helper integration site 1 (Jouberin) | | Nephronophthisis  Joubert syndrome 3  Intellectual disability | 6q23.3 | AR | Heterozygous *AHI1* variants are enriched in patients with homozygous *NPHP1* and neurological symptoms.29  More severe neurological disease in a patient with biallelic *CEP290* variants and a heterozygous *AHI1*.49  Heterozygous *AHI1* variants are associated with retinal disease irrespective of the underlying biallelic cause of Nephronophthisis.35 |
| *CC2D2A*51 | | | | | | Coiled-coil and C2 domain-containing 2A | | Nephronophthisis (possible mild)  Meckel-Gruber syndrome 6  Joubert syndrome 9  COACH syndrome 2  Hepatic fibrosis  Intellectual disability | 4p15.32 | AR | *TTC21B* contributes possible modifier alleles.63 |
| *TMEM237*143 | | | | | | Transmembrane protein 237 | | Nephronophthisis  Joubert syndrome 14  Meckel-Gruber syndrome | 2q33.1 | AR |  |
| *TMEM138*144 | | | | | | Transmembrane protein 138 | | Nephronophthisis (rare)  Joubert syndrome 16  Orofaciodigital syndrome | 11q12.2 | AR |  |
| *TMEM231*7 | | | | | | Transmembrane protein 231 | | Cystic kidneys  Joubert syndrome 20  Orofaciodigital syndrome 3  Meckel-Gruber syndrome 11 | 16q23.1 | AR |  |
| IFT122145 | | | | | | Intraflagellar transport 122 | | Nephronophthisis  Cranioectodermal dysplasia 1  Hepatic fibrosis | 3q21.3-q22.1 | AR |  |
| WDR35146 | | | | | | WD repeat domain 35 | | Nephronophthisis  Cranioectodermal dysplasia 2  Short-rib thoracic dysplasia 7  Hepatic fibrosis | 2p24.1 | AR |  |
| IFT43147 | | | | | | intraflagellar transport 43 | | Nephronophthisis  Cranioectodermal dysplasia 3  Short-rib thoracic dysplasia 18  Hepatic fibrosis | 14q24.3 | AR |  |
| *ALMS1*148 | | | | | | ALMS1 centrosome and basal body associated protein | | Alström syndrome | 2p13.1 | AR |  |
| Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) | | | | | | | | | | | |
| *UMOD*2 | | | | | | Uromodulin | | ADTKD-*UMOD* | 16p12.3 | AD | Common promoter variants are associated with the risk of CKD and hypertension.19,65–69,109,110  Biallelic variants are more severe.111 |
| *MUC1*112 | | | | | | Mucin 1, cell surface-associated | | ADTKD-*MUC1* | 1q22 | AD | Common splice site variant increases the risk of CKD18 |
| *HNF1B*115 | | | | | | HNF1 homeobox B | | ADTKD-*HNF1B* | 17q12 | AD | *HNF1B* has a role in transcriptional activation of *UMOD*, *PKHD1* and *PKD2* genes.116 |
| *REN*113 | | | | | | Renin | | ADTKD-*REN*  Renal tubular dysgenesis | 1q32.1 | AD  AR | Biallelic variants cause a more severe phenotype resulting in renal tubular dysgenesis114 |
| *SEC61A1*117 | | | | | | SEC61 translocon alpha 1 subunit | | ADTKD-*SEC61A1* | 3q21.3 | AD |  |
| *DNAJB11*3 | | | | | | DnaJ heat shock protein family (Hsp40) member B11 | | ADTKD/ADPKD 'hybrid'  Ivermark II syndrome - Renal-hepatic-pancreatic dysplasia (RHPD) | 3q27.3 | AD  AR | Biallelic variants cause a more severe phenotype with a fetal disease, including enlarged cystic kidneys, dilation and proliferation of pancreatic duct cells, and liver ductal plate malformation.118 |
| Mitochondrial disorders | | | | | | | | | | | |
| *MT-TF*4 | | | | | | Mitochondrially encoded tRNA-Phe (UUU/C) | | Mitochondrially inherited tubulointerstitial kidney disease (MITKD) | Mitochondria | Mitochondria |  |
| *MT-TL1*119 | | | | | | Mitochondrially encoded tRNA-Leu (UUA/G) 1 | | Mitochondrial Encephalopathy, Lactic acidosis, and Stroke-like episodes (MELAS)  Maternally inherited diabetes and deafness (MIDD) Syndromes | Mitochondria | Mitochondria | A possible modifying variant in tRNAlys in a family with m.3243A>G and MIDD rather than MELAS, the tRNAlys variant was absent in 75 controls.82 |
| Renal tubular dysgenesis | | | | | | | | | | | |
| *AGT*114 | | | | | | Angiotensinogen | | Renal tubular dysgenesis | 1q42.2 | AR |  |
| *AGTR1*114 | | | | | | Angiotensin II receptor type 1 | | Renal tubular dysgenesis | 3q24 | AR |  |
| *ACE*114 | | | | | | Angiotensin I converting enzyme | | Renal tubular dysgenesis | 17q23.3 | AR |  |
| Other | | | | | | | | | | | |
| *XPNPEP3*149 | | | | | | X-prolyl aminopeptidase 3 | | Nephronophthisis-like nephropathy 1 (NPHPL1) | 22q13.2 | AR |  |
| *GATM*150 | | | | | | Glycine amidinotransferase | | Fanconi syndrome and IFTA | 15q21.1 | AD |  |
| *SLC41A1*151 | | | | | | Solute carrier family 41 member 1 | | Nephronophthisis-like nephropathy | 1q32.1 | AR |  |
| *FAN1*152 | | | | | | FANCD2 and FANCI associated nuclease 1 | | Karyomegalic interstitial nephritis | 15q13.3 | AR |  |
| AD – autosomal dominant, ADTKD - Autosomal dominant tubulointerstitial kidney disease, ADPKD - Autosomal dominant polycystic kidney disease, AR – Autosomal recessive, COACH syndrome - Cerebellar vermis hypo/aplasia, oligophrenia, congenital ataxia, ocular coloboma, and hepatic fibrosis, ESKD – End-stage kidney disease, FSGS - Focal segmental glomerulosclerosis, MITKD - Mitochondrial inherited tubulointerstitial kidney disease. | | | | | | | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| HGNC gene symbol | HGNC approved gene name | Diagnosis | Gene Location | Assumed inheritance pattern | Evidence of Oligogenic/Modifier genes |
| Nephronophthisis | | | | | |
| *NPHP1*120,121 | Nephrocystin 1 | Nephronophthisis 1  Senior-Løken syndrome 1  Joubert syndrome 4  Bardet-Biedl syndrome | 2q13 | AR | Homozygous *NPHP1* is possibly modified by heterozygous *NPHP4* with early-onset ESKD.31  Heterozygous *AHI1* variants are enriched in patients with homozygous *NPHP1* and neurological symptoms.29 |
| *NPHP3*36 | Nephrocystin 3 | Nephronophthisis 3  Senior-Løken syndrome 3  Meckel-Gruber syndrome 7  Renal-hepatic-pancreatic dysplasia 1  Situs inversus  Hepatic fibrosis | 3q22.1 | AR | Possible digenic inheritance with *INVS.* 31  A heterozygous *NPHP4* variant may modify compound heterozygous *NPHP3* with early-onset ESKD and hepatic fibrosis.31,38  In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60 |
| *CEP290*39,40 | Centrosomal protein 290 | Nephronophthisis 6  Senior-Løken syndrome 6  Joubert syndrome  Bardet-Biedl syndrome 14  Hepatic fibrosis  Meckel-Gruber syndrome 4 | 12q21.32 | AR | Heterozygous pathogenic variants are present in several cases of homozygous *NPHP1* but with no evidence of modifier effect on phenotype.29  There is a more severe neurological disease in a patient with biallelic *CEP290* variants and a heterozygous *AHI1*.49  Possible triallelic disease with heterozygous *TMEM67* and homozygous *CEP290* variants in BBS.42  In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60  A variant in barttin CLCNK type accessory subunit beta *(BSND)* I significantly associated with kidney disease severity in patients with CEP290 variants.50 |
| *RPGRIP1L*55 | Retinitis pigmentosa GTPase regulator-interacting protein 1 like protein | Nephronophthisis 8  Joubert syndrome 7  COACH syndrome  Hepatic fibrosis  Meckel-Gruber syndrome 5 | 16q12.2 | AR | In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60 |
| *TTC21B*63 | Tetratricopeptide repeat domain 21B | Nephronophthisis 12  Joubert syndrome 11  Short-rib thoracic dysplasia  Focal segmental glomerulosclerosis (FSGS) | 2q24.3 | AR, AD | Both causal and a possible modifier of multiple ciliopathy genes including *BBS1, BBS2, BBS4, MKKS, BBS7, BBS10, BBS12, NPHP4, CC2D2A* and *TMEM216*.63  *TTC21B* is a possible modifier in patients with FSGS and collagen type 4 gene variants (*COL4A3* and *COL4A5).*62 |
| *INVS*122 | Inversin | Nephronophthisis 2  Situs inversus  Hepatic fibrosis | 9q31.1 | AR | Possible digenic inheritance with *NPHP3.*31 |
| *NPHP4*123,124 | Nephrocystin 4 | Nephronophthisis 4  Senior-Løken syndrome 4  Hepatic fibrosis | 1p36.1 | AR | Homozygous *NPHP1* possibly modified by heterozygous *NPHP4* with early-onset ESKD.31  Compound heterozygous *NPHP3* modified by heterozygous *NPHP4* variant with early-onset ESKD and hepatic fibrosis.31,38  *TTC21B* contributes possible modifier alleles to *NPHP4*.63 |
| *IQCB1*125 | IQ motif containing B1 | Nephronophthisis 5  Senior-Løken syndrome 5 | 3q13.33 | AR | Common variants are associated with elevated creatine in association studies.20  In patients with syndromic nephronophthisis caused by several genes including (including *NPHP3*, *IQCB1*, *CEP290* and *MKS1*), an additional heterozygous variant in *RPGRIP1L* is associated with retinitis pigmentosa.60 |
| *SDCCAG8*128 | Serologically defined colon cancer antigen 8 | Nephronophthisis 10  Senior-Løken syndrome 7  Bardet-Biedl syndrome 16  Intellectual disability | 1q43-q44 | AR | Common variants in *SDCCAG8* are associated with elevated creatine in association studies.20 |
| *TMEM67*129 | Transmembrane protein 67 | Nephronophthisis 11  Joubert syndrome 6  Meckel-Gruber syndrome 3  COACH syndrome  Hepatic fibrosis | 8q22.1 | AR | Possible triallelic disease in BBS contributing heterozygous *TMEM67* variants to homozygous truncating variants in *CEP290*.42  Possible triallelic disease contributing heterozygous *TMEM67* and homozygous *BBS9* variants in BBS.42 |
| *IFT172*133 | Intraflagellar transport 172 | Nephronophthisis 17  Bardet-Biedl syndrome  Short-rib thoracic dysplasia 10  Hepatic fibrosis | 2p23.3 | AR | Common variants in *IFT172* are associated with elevated creatine in association studies.20 |
| *TMEM216*141 | Transmembrane protein 216 | Nephronophthisis  Joubert syndrome 2  Meckel-Gruber syndrome 2  Orofaciodigital syndrome  Intellectual disability | 11q13.1 | AR | *TTC21B* contributes possible modifier alleles.63 |
| *AHI1*142 | Abelson helper integration site 1 (Jouberin) | Nephronophthisis  Joubert syndrome 3  Intellectual disability | 6q23.3 | AR | Heterozygous *AHI1* variants are enriched in patients with homozygous *NPHP1* and neurological symptoms.29  More severe neurological disease in a patient with biallelic *CEP290* variants and a heterozygous *AHI1*.49  Heterozygous *AHI1* variants are associated with retinal disease irrespective of the underlying biallelic cause of Nephronophthisis.35 |
| *CC2D2A*51 | Coiled-coil and C2 domain-containing 2A | Nephronophthisis (possible mild)  Meckel-Gruber syndrome 6  Joubert syndrome 9  COACH syndrome 2  Hepatic fibrosis  Intellectual disability | 4p15.32 | AR | *TTC21B* contributes possible modifier alleles.63 |
| *NEK8*127 | NIMA related kinase 8 | Nephronophthisis 9  Rena-hepatic-pancreatic-dysplasia 2  Hepatic fibrosis | 17q11.2 | AR |  |
| *WDR19*130 | WD repeat domain 19 | Nephronophthisis 13  Senior-Løken syndrome 8  Cranioectodermal dysplasia 4  Short-rib thoracic dysplasia 5  Hepatic fibrosis | 4p14 | AR |  |
| *ZNF423*131 | Zinc finger protein 423 | Nephronophthisis 14  Joubert syndrome 19  Situs inversus | 16q12.1 | AR, AD |  |
| *CEP164*131 | Centrosomal protein 164 | Nephronophthisis 15  Senior-Løken syndrome  Meckel-Gruber syndrome  Joubert syndrome  Hepatic fibrosis | 11q23.3 | AR |  |
| *ANKS6*132 | Ankyrin repeat and sterile alpha motif domain containing 6 | Nephronophthisis 16  Situs inversus  Hepatic fibrosis | 9q22.33 | AR |  |
| *CEP83*134 | Centrosomal protein 83 | Nephronophthisis 18  Intellectual disability  Hepatic fibrosis | 12q22 | AR |  |
| *DCDC2*135 | Doublecortin domain containing 2 | Nephronophthisis 19  Hepatic fibrosis  Non-syndromic recessive deafness | 6q22.3 | AR |  |
| *MAPKBP1*136 | Mitogen-activated protein kinase binding protein 1 | Nephronophthisis 20 | 15q15.1 | AR |  |
| *IFT81*137 | Intraflagellar transport 81 | Nephronophthisis  Short-rib thoracic dysplasia 19 | 12q24.11 | AR |  |
| *TRAF3IP1*138 | TRAF3 interacting protein 1 | Nephronophthisis  Senior-Løken syndrome 9  Intellectual disability | 2q37.3 | AR |  |
| *ADAMTS9*139 | ADAM metallopeptidase with thrombospondin type 1 motif 9 | Nephronophthisis | 3p14.1 | AR |  |
| *INPP5E*140 | Inositol polyphosphate-5-phosphatase E | Nephronophthisis  Joubert syndrome 1  Hepatic fibrosis  Intellectual disability | 9q34.3 | AR |  |
| *TMEM237*143 | Transmembrane protein 237 | Nephronophthisis  Joubert syndrome 14  Meckel-Gruber syndrome | 2q33.1 | AR |  |
| *TMEM138*144 | Transmembrane protein 138 | Nephronophthisis (rare)  Joubert syndrome 16  Orofaciodigital syndrome | 11q12.2 | AR |  |
| *TMEM231*7 | Transmembrane protein 231 | Cystic kidneys  Joubert syndrome 20  Orofaciodigital syndrome 3  Meckel-Gruber syndrome 11 | 16q23.1 | AR |  |
| IFT122145 | Intraflagellar transport 122 | Nephronophthisis  Cranioectodermal dysplasia 1  Hepatic fibrosis | 3q21.3-q22.1 | AR |  |
| WDR35146 | WD repeat domain 35 | Nephronophthisis  Cranioectodermal dysplasia 2  Short-rib thoracic dysplasia 7  Hepatic fibrosis | 2p24.1 | AR |  |
| IFT43147 | intraflagellar transport 43 | Nephronophthisis  Cranioectodermal dysplasia 3  Short-rib thoracic dysplasia 18  Hepatic fibrosis | 14q24.3 | AR |  |
| *ALMS1*148 | ALMS1 centrosome and basal body associated protein | Alström syndrome | 2p13.1 | AR |  |
| Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) | | | | | |
| *UMOD*2 | Uromodulin | ADTKD-*UMOD* | 16p12.3 | AD | Common promoter variants are associated with the risk of CKD and hypertension.19,65–69,109,110  Biallelic variants are more severe.111 |
| *MUC1*112 | Mucin 1, cell surface-associated | ADTKD-*MUC1* | 1q22 | AD | Common splice site variant increases the risk of CKD18 |
| *HNF1B*115 | HNF1 homeobox B | ADTKD-*HNF1B* | 17q12 | AD | *HNF1B* has a role in transcriptional activation of *UMOD*, *PKHD1* and *PKD2* genes.116 |
| *REN*113 | Renin | ADTKD-*REN*  Renal tubular dysgenesis | 1q32.1 | AD  AR | Biallelic variants cause a more severe phenotype resulting in renal tubular dysgenesis114 |
| *DNAJB11*3 | DnaJ heat shock protein family (Hsp40) member B11 | ADTKD/ADPKD 'hybrid'  Ivermark II syndrome - Renal-hepatic-pancreatic dysplasia (RHPD) | 3q27.3 | AD  AR | Biallelic variants cause a more severe phenotype with a fetal disease, including enlarged cystic kidneys, dilation and proliferation of pancreatic duct cells, and liver ductal plate malformation.118 |
| *SEC61A1*117 | SEC61 translocon alpha 1 subunit | ADTKD-*SEC61A1* | 3q21.3 | AD |  |
| Mitochondrial disorders | | | | | |
| *MT-TL1*119 | Mitochondrially encoded tRNA-Leu (UUA/G) 1 | Mitochondrial Encephalopathy, Lactic acidosis, and Stroke-like episodes (MELAS)  Maternally inherited diabetes and deafness (MIDD) Syndromes | Mitochondria | Mitochondria | A possible modifying variant in tRNAlys in a family with m.3243A>G and MIDD rather than MELAS, the tRNAlys variant was absent in 75 controls.82 |
| *MT-TF*4 | Mitochondrially encoded tRNA-Phe (UUU/C) | Mitochondrially inherited tubulointerstitial kidney disease (MITKD) | Mitochondria | Mitochondria |  |
| Renal tubular dysgenesis | | | | | |
| *AGT*114 | Angiotensinogen | Renal tubular dysgenesis | 1q42.2 | AR |  |
| *AGTR1*114 | Angiotensin II receptor type 1 | Renal tubular dysgenesis | 3q24 | AR |  |
| *ACE*114 | Angiotensin I converting enzyme | Renal tubular dysgenesis | 17q23.3 | AR |  |
| Other | | | | | |
| *XPNPEP3*149 | X-prolyl aminopeptidase 3 | Nephronophthisis-like nephropathy 1 (NPHPL1) | 22q13.2 | AR |  |
| *GATM*150 | Glycine amidinotransferase | Fanconi syndrome and IFTA | 15q21.1 | AD |  |
| *SLC41A1*151 | Solute carrier family 41 member 1 | Nephronophthisis-like nephropathy | 1q32.1 | AR |  |
| *FAN1*152 | FANCD2 and FANCI associated nuclease 1 | Karyomegalic interstitial nephritis | 15q13.3 | AR |  |
| AD – autosomal dominant, ADTKD - Autosomal dominant tubulointerstitial kidney disease, ADPKD - Autosomal dominant polycystic kidney disease, AR – Autosomal recessive, COACH syndrome - Cerebellar vermis hypo/aplasia, oligophrenia, congenital ataxia, ocular coloboma, and hepatic fibrosis, ESKD – End-stage kidney disease, FSGS - Focal segmental glomerulosclerosis, MITKD - Mitochondrial inherited tubulointerstitial kidney disease. | | | | | |

|  |
| --- |
| **Figure 2 - Simplifiedschematic representation of complex genetic inheritance from monogenic to polygenic (boxes represent genes, red vertical lines represent the pathogenic allele**).A spectrum of increasingly complex diseases may occur with additional mutated alleles from monoallelic through to multiallelic. Additional complexity arises due to the number of genes affected from one gene (monogenic), a few genes (oligogenic) or many genes (polygenic). Modifiers are variants that can alter the disease phenotype but are not required for the primary disease to be present. Modifiers can be additive or suppressive and can affect penetrance, expressivity and dominance. |

|  |
| --- |
| **Figure 3. The spectrum of disease associated with variants in centrosomal protein 290 (*CEP290*).** **a.** Eye involvement ranges from a relatively mild retinal phenotype to Leber congenital amaurosis (LCA), which is a leading cause of childhood blindness. **b.** Senior-Løken syndrome is characterised by retinal dystrophy and nephronophthisis. **c.** Joubert syndrome (JBTS) adds cerebellar vermis hypoplasia to retinal dystrophy and nephronophthisis. **d.** Bardet-Biedl syndrome is truly multisystem with significant features of retinal disease, central obesity, postaxial polydactyly, cognitive impairment, genitourinary abnormalities, and kidney disease. **e.** Meckel-Gruber syndrome is a lethal multisystem disorder with occipital meningo-encephalocele, hepatobiliary ductal plate malformation, postaxial polydactyly, and cystic dysplasia of the kidneys with marked interstitial fibrosis. |

|  |
| --- |
| **Figure 4. Gene regulatory networks in tubulointerstitial kidney disease with evidence of modifier genes, triallelic inheritance or gene interaction.** **A** Non-motile (primary) cilia dysfunction is a recognised driver of kidney disease, including nephronophthisis, polycystic kidney disease or cystic dysplasia (Figure 1). Cilia are membrane-bound organelles that resemble finger-like projections on the apical surface of many tissues, including renal tubular epithelia. The primary cilium is composed of a basal body consisting of triplets of microtubules (grey) from which the cilium assembles.160 **B** Hotspots for ciliopathies include the intraflagellar transport proteins (green) responsible for protein trafficking and signalling pathways, the inversin compartment (blue) controlling cell polarity, the transition zone (purple) involved in the cell cycle and control of the entry and exit of proteins and the BBSome (Bardet-Biedl syndrome proteins) (red) responsible for the trafficking of proteins to the cilia.160 This network of selected genes with evidence of modifier and triallelic inheritance reveals the close functional interaction of genes encoding the primary cilia. Solid lines represent modifier genes, and dashed lines represent genes with evidence for possible triallelic inheritance. The direction of the arrow denotes the direction of the contribution of additional variants to the primary mutated gene (e.g. homozygous variants in *NPHP1* and a third mutated allele in *AHI1* may result in a neurological phenotype like Joubert syndrome).29 Bidirectional arrows indicate the equal contribution of variants. **C** There is significant potential for cumulative variantal burden in genes downstream of the transcription factor hepatocyte nuclear factor 1β (*HNF1B*), to modify disease phenotypes. Evidence in mouse models suggests that several genes are downregulated with *Hnf1b* inactivation (dashed line).116 Downregulation of *UMOD* may also explain why most patients with *HNF1B* variants have hyperuricaemia typical of ADTKD-*UMOD*.161 Loss of *HNF1B* results in activation of a transcriptional network that induces extracellular matrix deposition and aberrant transforming growth factor 1 beta (*TGF1B*) signalling resulting in tubulointerstitial fibrosis.162 *HNF1B* is linked to mitochondrial dysfunction in renal epithelial cells in experimental studies through other transcription factors.163 Mitochondrial dysfunction in ADTKD-*UMOD* also results secondary to endoplasmic reticulum stress from retention of misfolded uromodulin protein. 83 Direct evidence of genetic modification is reported in a patient with heterozygous variants in both *PKD1* and *HNF1B,* causing early-onset severe disease.79 |

## References

1. Hildebrandt F, Attanasio M, Otto E. Nephronophthisis: Disease mechanisms of a ciliopathy. *Journal of the American Society of Nephrology*. 2009;20(1):23-35. doi:10.1681/ASN.2008050456

2. Hart TC. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. *J Med Genet*. 2002;39(12):882-892. doi:10.1136/jmg.39.12.882

3. Cornec-Le Gall E, Olson RJ, Besse W, et al. Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. *Am J Hum Genet*. 2018;102(5):832-844. doi:10.1016/j.ajhg.2018.03.013

4. Connor TM, Hoer S, Mallett A, et al. Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. Larsson NG, ed. *PLoS Genet*. 2017;13(3):e1006620. doi:10.1371/journal.pgen.1006620

5. Srour M, Hamdan FF, Schwartzentruber JA, et al. Mutations in TMEM231 cause joubert syndrome in french canadians. *J Med Genet*. 2012;49(10):636-641. doi:10.1136/jmedgenet-2012-101132

6. Shaheen R, Ansari S, Mardawi E Al, Alshammari MJ, Alkuraya FS. Mutations in TMEM231 cause Meckel-Gruber syndrome. *J Med Genet*. 2013;50(3):160-162. doi:10.1136/jmedgenet-2012-101431

7. Roberson EC, Dowdle WE, Ozanturk A, et al. TMEM231, mutated in orofaciodigital and Meckel syndromes, organizes the ciliary transition zone. *Journal of Cell Biology*. 2015;209(1):129-142. doi:10.1083/jcb.201411087

8. Havrilla JM, Pedersen BS, Layer RM, Quinlan AR. A map of constrained coding regions in the human genome. *Nat Genet*. 2019;51(1):88-95. doi:10.1038/s41588-018-0294-6

9. Moskowitz JL, Piret SE, Lhotta K, et al. Association between genotype and phenotype in uromodulin-associated kidney disease. *Clinical Journal of the American Society of Nephrology*. 2013;8(8):1349-1357. doi:10.2215/CJN.11151012

10. Walia S, Fishman GA, Swaroop A, et al. Discordant Phenotypes in Fraternal Twins Having an Identical Mutation in Exon ORF15 of the RPGR Gene. *Archives of Ophthalmology*. 2008;126(3):379. doi:10.1001/archophthalmol.2007.72

11. Zaki MS, Sattar S, Massoudi RA. Co-occurrence of distinct ciliopathy diseases in single families suggests genetic modifiers. *Am J Med Genet A*. 2011;155(12):3042-3049. doi:http://dx.doi.org/10.1002/ajmg.a.34173

12. Maglic D, Stephen J, Malicdan MC V., et al. TMEM231 Gene Conversion Associated with Joubert and Meckel–Gruber Syndromes in the Same Family. *Hum Mutat*. 2016;37(11):1144-1148. doi:10.1002/humu.23054

13. Wolf MTF. Nephronophthisis and related syndromes. *Curr Opin Pediatr*. 2015;27(2):201-211. doi:10.1097/MOP.0000000000000194

14. Kidd K, Vylet’al P, Schaeffer C, et al. Genetic and Clinical Predictors of Age of ESKD in Individuals With Autosomal Dominant Tubulointerstitial Kidney Disease Due to UMOD Mutations. *Kidney Int Rep*. 2020;5(9):1472-1485. doi:10.1016/j.ekir.2020.06.029

15. Hopp K, Cornec-Le Gall E, Senum SR, et al. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. *Kidney Int*. 2020;97(2):370-382. doi:10.1016/j.kint.2019.08.038

16. Khera A V., Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet*. 2018;50(9):1219-1224. doi:10.1038/s41588-018-0183-z

17. Fahed AC, Wang M, Homburger JR, et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. *Nat Commun*. 2020;11(1):1-9. doi:10.1038/s41467-020-17374-3

18. Xu X, Eales JM, Akbarov A, et al. Molecular insights into genome-wide association studies of chronic kidney disease-defining traits. *Nat Commun*. 2018;9(1):4800. doi:10.1038/s41467-018-07260-4

19. Trudu M, Janas S, Lanzani C, et al. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. *Nat Med*. 2013;19(12):1655-1660. doi:10.1038/nm.3384

20. Drivas TG, Lucas A, Zhang X, Ritchie MDR. Mendelian pathway analysis of laboratory traits reveals distinct roles for ciliary subcompartments in common disease pathogenesis. *bioRxiv*. Published online February 25, 2020. doi:10.1101/2020.08.31.275685

21. Karczewski KJ, Solomonson M, Chao KR, et al. Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. *Cell genomics*. 2022;2(9):100168. doi:10.1016/j.xgen.2022.100168

22. Génin E, Feingold J, Clerget-Darpoux F. Identifying modifier genes of monogenic disease: Strategies and difficulties. *Hum Genet*. 2008;124(4):357-368. doi:10.1007/s00439-008-0560-2

23. Kousi M, Katsanis N. Genetic modifiers and oligogenic inheritance. *Cold Spring Harb Perspect Med*. 2015;5(6):1-22. doi:10.1101/cshperspect.a017145

24. Nadeau JH. Modifier genes in mice and humans. *Nat Rev Genet*. 2001;2(3):165-174. doi:10.1038/35056009

25. Norman CS, O’Gorman L, Gibson J, et al. Identification of a functionally significant tri-allelic genotype in the Tyrosinase gene (TYR) causing hypomorphic oculocutaneous albinism (OCA1B). *Sci Rep*. 2017;7(1). doi:10.1038/s41598-017-04401-5

26. Halbritter J, Porath JD, Diaz KA, et al. Identification of 99 novel mutations in a worldwide cohort of 1,056 patients with a nephronophthisis-related ciliopathy. *Hum Genet*. 2013;132(8):865-884. doi:10.1007/s00439-013-1297-0

27. Braun DA, Hildebrandt F. Ciliopathies. *Cold Spring Harb Perspect Biol*. 2017;9(3):a028191. doi:10.1101/cshperspect.a028191

28. Saunier S, Calado J, Benessy F, et al. Characterization of the NPHP1 locus: Mutational mechanism involved in deletions in familial juvenile nephronophthisis. *Am J Hum Genet*. 2000;66(3):778-789. doi:10.1086/302819

29. Tory K, Lacoste T, Burglen L, et al. High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: Potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. *Journal of the American Society of Nephrology*. 2007;18(5):1566-1575. doi:10.1681/ASN.2006101164

30. Snoek R, van Setten J, Keating BJ, et al. NPHP1 (Nephrocystin-1) gene deletions cause adult-onset ESRD. *Journal of the American Society of Nephrology*. 2018;29(6):1772-1779. doi:http://dx.doi.org/10.1681/ASN.2017111200

31. Hoefele J, Wolf MTF, O’Toole JF, et al. Evidence of oligogenic inheritance in nephronophthisis. *Journal of the American Society of Nephrology*. 2007;18(10):2789-2795. doi:10.1681/ASN.2007020243

32. Caridi G, Murer L, Bellantuono R, et al. Renal-retinal syndromes: association of retinal anomalies and recessive nephronophthisis in patients with homozygous deletion of the NPH1 locus. *Am J Kidney Dis*. 1998;32(6):1059-1062.

33. Parisi MA, Bennett CL, Eckert ML, et al. The NPHP1 gene deletion associated with juvenile nephronophthisis is present in a subset of individuals with Joubert syndrome. *Am J Hum Genet*. 2004;75(1):82-91. doi:10.1086/421846

34. Lindstrand A, Davis EE, Carvalho CMB, et al. Recurrent CNVs and SNVs at the NPHP1 locus contribute pathogenic alleles to Bardet-Biedl syndrome. *Am J Hum Genet*. 2014;94(5):745-754. doi:10.1016/j.ajhg.2014.03.017

35. Louie CM, Caridi G, Lopes VS, et al. AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration in nephronophthisis. *Nat Genet*. 2010;42(2):175-180. doi:10.1038/ng.519

36. Olbrich H, Fliegauf M, Hoefele J, et al. Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. *Nat Genet*. 2003;34(4):455-459. doi:10.1038/ng1216

37. Tory K, Rousset-Rouvière C, Gubler MC, et al. Mutations of NPHP2 and NPHP3 in infantile nephronophthisis. *Kidney Int*. 2009;75(8):839-847. doi:http://dx.doi.org/10.1038/ki.2008.662

38. Penchev V, Boueva A, Kamenarova K, et al. A familial case of severe infantile nephronophthisis explained by oligogenic inheritance. *Eur J Med Genet*. 2017;60(6):321-325. doi:10.1016/j.ejmg.2017.04.002

39. Sayer JA, Otto EA, O’Toole JF, et al. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. *Nat Genet*. 2006;38(6):674-681. doi:10.1038/ng1786

40. Valente EM, Silhavy JL, Brancati F, et al. Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. *Nat Genet*. 2006;38(6):623-625. doi:10.1038/ng1805

41. Den Hollander AI, Koenekoop RK, Yzer S, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of leber congenital amaurosis. *Am J Hum Genet*. 2006;79(3):556-561. doi:10.1086/507318

42. Leitch CC, Zaghloul NA, Davis EE, et al. Hypomorphic mutations in syndromic encephalocele genes are associated with Bardet-Biedl syndrome. *Nat Genet*. 2008;40(4):443-448. doi:10.1038/ng.97

43. Baala L, Romano S, Khaddour R, et al. The Meckel-Gruber syndrome gene, MKS3, is mutated in Joubert syndrome. *Am J Hum Genet*. 2007;80(1):186-194. doi:10.1086/510499

44. Helou J, Otto EA, Attanasio M, et al. Mutation analysis of NPHP6/CEP290 in patients with Joubert syndrome ana Senior-Løken syndrome. *J Med Genet*. 2007;44(10):657-663. doi:10.1136/jmg.2007.052027

45. Frank V, Den Hollander AI, Brüchle NO, et al. Mutations of the CEP290 gene encoding a centrosomal protein cause meckel-gruber syndrome. *Hum Mutat*. 2008;29(1):45-52. doi:10.1002/humu.20614

46. Wheway G, Lord J, Baralle D. Splicing in the pathogenesis, diagnosis and treatment of ciliopathies. *Biochim Biophys Acta Gene Regul Mech*. 2019;1862(11-12):194433. doi:10.1016/j.bbagrm.2019.194433

47. Cummings BB, Karczewski KJ, Kosmicki JA, et al. Transcript expression-aware annotation improves rare variant interpretation. *Nature*. 2020;581(7809):452-458. doi:10.1038/s41586-020-2329-2

48. Vidal-Petiot E, Cheval L, Faugeroux J, et al. A new methodology for quantification of alternatively spliced exons reveals a highly tissue-specific expression pattern of WNK1 isoforms. Feraille E, ed. *PLoS One*. 2012;7(5):e37751. doi:10.1371/journal.pone.0037751

49. Coppieters F, Casteels I, Meire F, et al. Genetic screening of LCA in Belgium: predominance of CEP290 and identification of potential modifier alleles in AHI1 of CEP290-related phenotypes. *Hum Mutat*. 2010;31(10):E1709-E1766. doi:10.1002/humu.21336

50. Ramsbottom SA, Thelwall PE, Wood KM, et al. Mouse genetics reveals Barttin as a genetic modifier of Joubert syndrome. *Proc Natl Acad Sci U S A*. 2020;117(2):1113-1118. doi:10.1073/pnas.1912602117

51. Gorden NT, Arts HH, Parisi MA, et al. CC2D2A Is Mutated in Joubert Syndrome and Interacts with the Ciliopathy-Associated Basal Body Protein CEP290. *Am J Hum Genet*. 2008;83(5):559-571. doi:10.1016/j.ajhg.2008.10.002

52. Schäfer T, Pütz M, Lienkamp S, et al. Genetic and physical interaction between the NPHP5 and NPHP6 gene products. *Hum Mol Genet*. 2008;17(23):3655-3662. doi:10.1093/hmg/ddn260

53. Zhang Y, Seo S, Bhattarai S, et al. BBS mutations modify phenotypic expression of CEP290-related ciliopathies. *Hum Mol Genet*. 2014;23(1):40-51. doi:10.1093/hmg/ddt394

54. Arts HH, Doherty D, Van Beersum SEC, et al. Mutations in the gene encoding the basal body protein RPGRIP1L, a nephrocystin-4 interactor, cause Joubert syndrome. *Nat Genet*. 2007;39(7):882-888. doi:http://dx.doi.org/10.1038/ng2069

55. Delous M, Baala L, Salomon R, et al. The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome. *Nat Genet*. 2007;39(7):875-881. doi:http://dx.doi.org/10.1038/ng2039

56. Wolf MTF, Saunier S, O’Toole JF, et al. Mutational analysis of the RPGRIP1L gene in patients with Joubert syndrome and nephronophthisis. *Kidney Int*. 2007;72(12):1520-1526. doi:10.1038/sj.ki.5002630

57. Otto EA, Ramaswami G, Janssen S, et al. Mutation analysis of 18 nephronophthisis associated ciliopathy disease genes using a DNA pooling and next generation sequencing strategy. *J Med Genet*. 2011;48(2):105-116. doi:10.1136/jmg.2010.082552

58. Brancati F, Travaglini L, Zablocka D, et al. RPGRIP1L mutations are mainly associated with the cerebello-renal phenotype of Joubert syndrome-related disorders. *Clin Genet*. 2008;74(2):164-170. doi:10.1111/j.1399-0004.2008.01047.x

59. Kroes HY, Monroe GR, van der Zwaag B, et al. Joubert syndrome: genotyping a Northern European patient cohort. *European Journal of Human Genetics*. 2016;24(2):214-220. doi:10.1038/ejhg.2015.84

60. Khanna H, Davis EE, Murga-Zamalloa CA, et al. A common allele in RPGRIP1L is a modifier of retinal degeneration in ciliopathies. *Nat Genet*. 2009;41(6):739-745. doi:10.1038/ng.366

61. Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. *bioRxiv*. Published online January 30, 2019:531210. doi:10.1101/531210

62. Bullich G, Vargas I, Trujillano D, et al. Contribution of the TTC21B gene to glomerular and cystic kidney diseases. *Nephrology Dialysis Transplantation*. 2017;32(1):151-156. doi:http://dx.doi.org/10.1093/ndt/gfv453

63. Davis EE, Zhang Q, Liu Q, et al. TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. *Nat Genet*. 2011;43(3):189-196. doi:10.1038/ng.756

64. Clain J, Fritsch J, Lehmann-Che J, et al. Two Mild Cystic Fibrosis-associated Mutations Result in Severe Cystic Fibrosis When Combined in Cis and Reveal a Residue Important for Cystic Fibrosis Transmembrane Conductance Regulator Processing and Function. *Journal of Biological Chemistry*. 2001;276(12):9045-9049. doi:10.1074/jbc.M008979200

65. Köttgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. *Nat Genet*. 2009;41(6):712-717. doi:10.1038/ng.377

66. Böger CA, Gorski M, Li M, et al. Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. Kim SK, ed. *PLoS Genet*. 2011;7(9):e1002292. doi:10.1371/journal.pgen.1002292

67. Gudbjartsson DF, Holm H, Indridason OS, et al. Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases. McCarthy MI, ed. *PLoS Genet*. 2010;6(7):1-9. doi:10.1371/journal.pgen.1001039

68. Padmanabhan S, Melander O, Johnson T, et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. *PLoS Genet*. 2010;6(10):1-11. doi:10.1371/journal.pgen.1001177

69. Ghirotto S, Tassi F, Barbujani G, et al. The Uromodulin Gene Locus Shows Evidence of Pathogen Adaptation through Human Evolution. *Journal of the American Society of Nephrology*. 2016;27(10):2983-2996. doi:10.1681/asn.2015070830

70. Rezende-Lima W, Parreira KS, Garcia-Gonzalez M, Riveira E, Banet JF, Lens XM. Homozygosity for uromodulin disorders: FJHN and MCKD-type 2. *Kidney Int*. 2004;66(2):558-563. doi:http://dx.doi.org/10.1111/j.1523-1755.2004.00774.x

71. Edwards N, Olinger E, Adam J, et al. A novel homozygous UMOD mutation reveals gene dosage effects on uromodulin processing and urinary excretion. *Nephrology Dialysis Transplantation*. 2017;32(12):1994-1999. doi:10.1093/ndt/gfx066

72. Kirby A, Gnirke A, Jaffe DB, et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. *Nat Genet*. 2013;45(3):299-303. doi:http://dx.doi.org/10.1038/ng.2543

73. Bleyer AJ, Kmoch S, Antignac C, et al. Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. *Clinical Journal of the American Society of Nephrology*. 2014;9(3):527-535. doi:10.2215/CJN.06380613

74. Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocyte nuclear factor-1β and their related phenotypes. *J Med Genet*. 2006;43(1):84-90. doi:10.1136/jmg.2005.032854

75. Chen YZ, Gao Q, Zhao XZ, et al. Systematic review of TCF2 anomalies in renal cysts and diabetes syndrome/maturity onset diabetes of the young type 5. *Chin Med J (Engl)*. 2010;123(22):3326-3333. doi:10.3760/cma.j.issn.0366-6999.2010.22.029

76. Heidet L, Decramer S, Pawtowski A, et al. Spectrum of HNF1B mutations in a large cohort of patients who harbor renal diseases. *Clinical Journal of the American Society of Nephrology*. 2010;5(6):1079-1090. doi:10.2215/CJN.06810909

77. Clissold RL, Shaw-Smith C, Turnpenny P, et al. Chromosome 17q12 microdeletions but not intragenic HNF1B mutations link developmental kidney disease and psychiatric disorder. *Kidney Int*. 2016;90(1):203-211. doi:10.1016/j.kint.2016.03.027

78. Clissold RL, Ashfield B, Burrage J, et al. Genome-wide methylomic analysis in individuals with HNF1B intragenic mutation and 17q12 microdeletion. *Clin Epigenetics*. 2018;10(1):97. doi:10.1186/s13148-018-0530-z

79. Bergmann C, Von Bothmer J, Brüchle NO, et al. Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. *Journal of the American Society of Nephrology*. 2011;22(11):2047-2056. doi:10.1681/ASN.2010101080

80. Che R, Yuan Y, Huang S, Zhang A. Mitochondrial dysfunction in the pathophysiology of renal diseases. *Am J Physiol Renal Physiol*. 2014;306(4):F367-F378. doi:10.1152/ajprenal.00571.2013

81. Guéry B, Choukroun G, Noël LH, et al. The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. *Journal of the American Society of Nephrology*. 2003;14(8):2099-2108. doi:10.1097/01.ASN.0000080180.51098.02

82. van den Ouweland JMW, Lemkes HHPJ, Ruitenbeek W, et al. Mutation in mitochondrial tRNALeu(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. *Nat Genet*. 1992;1(5):368-371. doi:10.1038/ng0892-368

83. Kemter E, Fröhlich T, Arnold GJ, Wolf E, Wanke R. Mitochondrial Dysregulation Secondary to Endoplasmic Reticulum Stress in Autosomal Dominant Tubulointerstitial Kidney Disease - UMOD (ADTKD-UMOD). *Sci Rep*. 2017;7(1):42970. doi:10.1038/srep42970

84. Forsythe E, Sparks K, Best S, et al. Risk Factors for Severe Renal Disease in Bardet-Biedl Syndrome. *J Am Soc Nephrol*. 2017;28:963-970. doi:10.1681/ASN.2015091029

85. Katsanis N, Ansley SJ, Badano JL, et al. Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. *Science (1979)*. 2001;293(5538):2256-2259. doi:10.1126/science.1063525

86. Beales PL, Badano JL, Ross AJ, et al. Genetic interaction of BBS1 mutations with alleles at other BBS loci can result in non-Mendelian Bardet-Biedl syndrome. *Am J Hum Genet*. 2003;72(5):1187-1199. doi:10.1086/375178

87. Badano JL, Leitch CC, Ansley SJ, et al. Dissection of epistasis in oligogenic Bardet-Biedl syndrome. *Nature*. 2006;439(7074):326-330. doi:10.1038/nature04370

88. Katsanis N. The oligogenic properties of Bardet-Biedl syndrome. *Hum Mol Genet*. 2004;13(90001):65R - 71. doi:10.1093/hmg/ddh092

89. Mykytyn K, Nishimura DY, Searby CC, et al. Identification of the gene (BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human obesity syndrome. *Nat Genet*. 2002;31(4):435-438. doi:10.1038/ng935

90. Mykytyn K, Nishimura DY, Searby CC, et al. Evaluation of complex inheritance involving the most common Bardet-Biedl syndrome locus (BBS1). *Am J Hum Genet*. 2003;72(2):429-437. doi:10.1086/346172

91. Abu-Safieh L, Al-Anazi S, Al-Abdi L, et al. In search of triallelism in Bardet-Biedl syndrome. *European Journal of Human Genetics*. 2012;20(4):420-427. doi:10.1038/ejhg.2011.205

92. Hichri H, Stoetzel C, Laurier V, et al. Testing for triallelism: Analysis of six BBS genes in a Bardet-Biedl syndrome family cohort. *European Journal of Human Genetics*. 2005;13(5):607-616. doi:10.1038/sj.ejhg.5201372

93. Bandano JL, Kim JC, Hoskins BE, et al. Heterozygous mutations in BBS1, BBS2 and BBS6 have a potential epistatic effect on Bardet-Beidl patients with two mutations at a second BBS locus. *Hum Mol Genet*. 2003;12(14):1651-1659. doi:10.1093/hmg/ddg188

94. Katsanis N, Eichers ER, Ansley SJ, et al. BBS4 is a minor contributor to Bardet-Biedl syndrome and may also participate in triallelic inheritance. *Am J Hum Genet*. 2002;71(1):22-29. doi:10.1086/341031

95. Kousi M, Söylemez O, Ozanturk A, et al. Evidence for secondary-variant genetic burden and non-random distribution across biological modules in a recessive ciliopathy. *Nat Genet*. 2020;52(11):1145-1150. doi:10.1038/s41588-020-0707-1

96. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. *J Med Genet*. 1999;36(6):437-446. doi:10.1136/JMG.36.6.437

97. Fauser S, Munz M, Besch D. Further support for digenic inheritance in Bardet-Biedl syndrome. *J Med Genet*. 2003;40(8). doi:10.1136/jmg.40.8.e104

98. Badano JL, Ansley SJ, Leitch CC, Lewis RA, Lupski JR, Katsanis N. Identification of a novel Bardet-Biedl syndrome protein, BBS7, that shares structural features with BBS1 and BBS2. *Am J Hum Genet*. 2003;72(3):650-658. doi:10.1086/368204

99. Massa F, Garbay S, Bouvier R, et al. Hepatocyte nuclear factor 1β controls nephron tubular development. *Development (Cambridge)*. 2013;140(4):886-896. doi:10.1242/dev.086546

100. Eckardt KU, Alper SL, Antignac C, et al. Autosomal dominant tubulointerstitial kidney disease: Diagnosis, classification, and management - A KDIGO consensus report. *Kidney Int*. 2015;88(4):676-683. doi:10.1038/ki.2015.28

101. Slaats GG, Lilien MR, Giles RH. Nephronophthisis: should we target cysts or fibrosis? *Pediatric Nephrology*. 2016;31(4):545-554. doi:10.1007/s00467-015-3162-y

102. Bolignano D, Zoccali C. Non-proteinuric rather than proteinuric renal diseases are the leading cause of end-stage kidney disease. *Nephrology Dialysis Transplantation*. 2017;32(suppl\_2):ii194-ii199. doi:10.1093/ndt/gfw440

103. Hildebrandt F, Zhou W. Nephronophthisis-associated ciliopathies. *Journal of the American Society of Nephrology*. 2007;18(6):1855-1871. doi:10.1681/ASN.2006121344

104. Živná M, Hůlková H, Matignon M, et al. Dominant Renin Gene Mutations Associated with Early-Onset Hyperuricemia, Anemia, and Chronic Kidney Failure. *Am J Hum Genet*. 2009;85(2):204-213. doi:10.1016/j.ajhg.2009.07.010

105. Riedhammer KM, Braunisch MC, Günthner R, et al. Exome Sequencing and Identification of Phenocopies in Patients With Clinically Presumed Hereditary Nephropathies. *American Journal of Kidney Diseases*. 2020;76(4):460-470. doi:10.1053/j.ajkd.2019.12.008

106. Van Der Ven AT, Connaughton DM, Ityel H, et al. Whole-exome sequencing identifies causative mutations in families with congenital anomalies of the kidney and urinary tract. *Journal of the American Society of Nephrology*. 2018;29(9):2348-2361. doi:10.1681/ASN.2017121265

107. Sheng X, Guan Y, Ma Z, et al. Mapping the genetic architecture of human traits to cell types in the kidney identifies mechanisms of disease and potential treatments. *Nat Genet*. 2021;53(9):1322-1333. doi:10.1038/s41588-021-00909-9

108. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine*. 2015;17(5):405-424. doi:10.1038/gim.2015.30

109. Köttgen A, Hwang SJ, Larson MG, et al. Uromodulin Levels Associate with a Common UMOD Variant and Risk for Incident CKD. *Journal of the American Society of Nephrology*. 2009;21(2):337-344. doi:10.1681/asn.2009070725

110. Devuyst O, Pattaro C. The UMOD Locus: Insights into the Pathogenesis and Prognosis of Kidney Disease. *Journal of the American Society of Nephrology*. 2018;29:713-726. doi:10.1681/asn.2017070716

111. Rezende-Lima W, Parreira KS, García-González M, Riveira E, Banet JF, Lens XM. Homozygosity for uromodulin disorders: FJHN and MCKD-type 2. *Kidney Int*. 2004;66(2):558-563. doi:10.1111/j.1523-1755.2004.00774.x

112. Kirby A, Gnirke A, Jaffe DB, et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. *Nature Publishing Group*. 2013;45. doi:10.1038/ng.2543

113. Stibůrková B, Majewski J, Hodaňová K, et al. Familial juvenile hyperuricaemic nephropathy (FJHN): Linkage analysis in 15 families, physical and transcriptional characterisation of the FJHN critical region on chromosome 16p11.2 and the analysis of seven candidate genes. *European Journal of Human Genetics*. 2003;11(2):145-154. doi:10.1038/sj.ejhg.5200937

114. Gribouval O, Gonzales M, Neuhaus T, et al. Mutations in genes in the renin-angiotensin system are associated with autosomal recessive renal tubular dysgenesis. *Nat Genet*. 2005;37(9):964-968. doi:10.1038/ng1623

115. Lindner TH, Njolstad PR, Horikawa Y, Bostad L, Bell GI, Sovik O. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. *Hum Mol Genet*. 1999;8(11):2001-2008.

116. Gresh L, Fischer E, Reimann A, et al. A transcriptional network in polycystic kidney disease. *EMBO Journal*. 2004;23(7):1657-1668. doi:10.1038/sj.emboj.7600160

117. Bolar NA, Golzio C, Živná M, et al. Heterozygous Loss-of-Function SEC61A1 Mutations Cause Autosomal-Dominant Tubulo-Interstitial and Glomerulocystic Kidney Disease with Anemia. *Am J Hum Genet*. 2016;99(1):174-187. doi:10.1016/j.ajhg.2016.05.028

118. Jordan P, Arrondel C, Bessières B, et al. Bi-allelic pathogenic variations in DNAJB11 cause Ivemark II syndrome, a renal-hepatic-pancreatic dysplasia. *Kidney Int*. 2021;99(2):405-409. doi:10.1016/j.kint.2020.09.029

119. Yasukawa T, Suzuki T, Suzuki T, Ueda T, Ohta S, Watanabe K. Modification defect at anticodon wobble nucleotide of mitochondrial tRNAs(Leu)(UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. *Journal of Biological Chemistry*. 2000;275(6):4251-4257. doi:10.1074/jbc.275.6.4251

120. Hildebrandt F, Otto E, Rensing C, et al. A novel gene encoding an SH3 domain protein is mutated in nephronophthisis type 1. *Nat Genet*. 1997;17(2):149-153. doi:10.1038/ng1097-149

121. Saunier S. A novel gene that encodes a protein with a putative src homology 3 domain is a candidate gene for familial juvenile nephronophthisis. *Hum Mol Genet*. 1997;6(13):2317-2323. doi:10.1093/hmg/6.13.2317

122. Otto EA, Schermer B, Obara T, et al. Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. *Nat Genet*. 2003;34(4):413-420. doi:10.1038/ng1217

123. Mollet G, Salomon R, Gribouval O, et al. The gene mutated in juvenile nephronophthisis type 4 encodes a novel protein that interacts with nephrocystin. *Nat Genet*. 2002;32(2):300-305. doi:http://dx.doi.org/10.1038/ng996

124. Otto E, Hoefele J, Ruf R, et al. A gene mutated in nephronophthisis and retinitis pigmentosa encodes a novel protein, nephroretinin, conserved in evolution. *Am J Hum Genet*. 2002;71(5):1161-1167. doi:http://dx.doi.org/10.1086/344395

125. Otto EA, Loeys B, Khanna H, et al. Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. *Nat Genet*. 2005;37(3):282-288. doi:10.1038/ng1520

126. Attanasio M, Uhlenhaut NH, Sousa VH, et al. Loss of GLIS2 causes nephronophthisis in humans and mice by increased apoptosis and fibrosis. *Nat Genet*. 2007;39(8):1018-1024. doi:http://dx.doi.org/10.1038/ng2072

127. Otto EA, M.L. T, U.T. S, et al. NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis. *Journal of the American Society of Nephrology*. 2008;19(3):587-592. doi:http://dx.doi.org/10.1681/ASN.2007040490

128. Otto EA, Hurd TW, Airik R, et al. Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. *Nat Genet*. 2010;42(10):840-850. doi:http://dx.doi.org/10.1038/ng.662

129. Otto EA, Tory K, Attanasio M, et al. Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11). *J Med Genet*. 2009;46(10):663-670. doi:http://dx.doi.org/10.1136/jmg.2009.066613

130. Bredrup C, Saunier S, Oud MM, et al. Ciliopathies with skeletal anomalies and renal insufficiency due to mutations in the IFT-A gene WDR19. *Am J Hum Genet*. 2011;89(5):634-643. doi:10.1016/j.ajhg.2011.10.001

131. Chaki M, Airik R, Ghosh AK, et al. Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. *Cell*. 2012;150(3):533-548. doi:http://dx.doi.org/10.1016/j.cell.2012.06.028

132. Hoff S, Halbritter J, Epting D, et al. ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3. *Nat Genet*. 2013;45(8):951-956. doi:10.1038/ng.2681

133. Halbritter J, Bizet AA, Schmidts M, et al. Defects in the IFT-B component IFT172 cause jeune and mainzer-saldino syndromes in humans. *Am J Hum Genet*. 2013;93(5):915-925. doi:http://dx.doi.org/10.1016/j.ajhg.2013.09.012

134. Failler M, Gee HY, Krug P, et al. Mutations of CEP83 cause infantile nephronophthisis and intellectual disability. *Am J Hum Genet*. 2014;94(6):905-914. doi:http://dx.doi.org/10.1016/j.ajhg.2014.05.002

135. Schueler M, Braun DA, Chandrasekar G, et al. DCDC2 Mutations Cause a Renal-Hepatic Ciliopathy by Disrupting Wnt Signaling. *The American Journal of Human Genetics*. 2015;96(1):81-92. doi:10.1016/J.AJHG.2014.12.002

136. Macia MS, Halbritter J, Delous M, et al. Mutations in MAPKBP1 Cause Juvenile or Late-Onset Cilia-Independent Nephronophthisis. *Am J Hum Genet*. 2017;100(2):323-333. doi:10.1016/j.ajhg.2016.12.011

137. Perrault I, Halbritter J, Porath JD, et al. IFT81, encoding an IFT-B core protein, as a very rare cause of a ciliopathy phenotype. *J Med Genet*. 2015;52(10):657-665. doi:10.1136/jmedgenet-2014-102838

138. Bizet AA, Becker-Heck A, Ryan R, et al. Mutations in TRAF3IP1/IFT54 reveal a new role for IFT proteins in microtubule stabilization. *Nat Commun*. 2015;6(1):8666. doi:10.1038/ncomms9666

139. Choi YJ, Halbritter J, Braun DA, et al. Mutations of ADAMTS9 Cause Nephronophthisis-Related Ciliopathy. *Am J Hum Genet*. 2019;104(1):45-54. doi:10.1016/j.ajhg.2018.11.003

140. Bielas SL, Silhavy JL, Brancati F, et al. Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. *Nat Genet*. 2009;41(9):1032-1036. doi:http://dx.doi.org/10.1038/ng.423

141. Valente EM, Logan C V, Mougou-Zerelli S, et al. Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. *Nat Genet*. 2010;42(7):619-625. doi:10.1038/ng.594

142. Ferland RJ, Eyaid W, Collura R V, et al. Abnormal cerebellar development and axonal decussation due to mutations in AHI1 in Joubert syndrome. *Nat Genet*. 2004;36(9):1008-1013. doi:10.1038/ng1419

143. Huang L, Szymanska K, Jensen VL, et al. TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. *Am J Hum Genet*. 2011;89(6):713-730. doi:10.1016/j.ajhg.2011.11.005

144. Lee JH, Silhavy JL, Lee JE, et al. Evolutionarily assembled cis-regulatory module at a human ciliopathy locus. *Science (1979)*. 2012;335(6071):966-969. doi:10.1126/science.1213506

145. Alazami AM, Seidahmed MZ, Alzahrani F, Mohammed AO, Alkuraya FS. Novel ift122 mutation associated with impaired ciliogenesis and cranioectodermal dysplasia. *Mol Genet Genomic Med*. 2014;2(2):103-106. doi:10.1002/mgg3.44

146. Gilissen C, Arts HH, Hoischen A, et al. Exome sequencing identifies WDR35 variants involved in Sensenbrenner syndrome. *Am J Hum Genet*. 2010;87(3):418-423. doi:10.1016/j.ajhg.2010.08.004

147. Arts HH, Bongers EMHF, Mans DA, et al. C14ORF179 encoding IFT43 is mutated in Sensenbrenner syndrome. *J Med Genet*. 2011;48(6):390-395. doi:10.1136/jmg.2011.088864

148. Hearn T, Renforth GL, Spalluto C, et al. Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome. *Nat Genet*. 2002;31(1):79-83. doi:10.1038/ng874

149. O’Toole JF, Liu Y, Davis EE, et al. Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathy. *Journal of Clinical Investigation*. 2010;120(3):791-802. doi:http://dx.doi.org/10.1172/JCI40076

150. Reichold M, Klootwijk ED, Reinders J, et al. Glycine Amidinotransferase (GATM), Renal Fanconi Syndrome, and Kidney Failure. *Journal of the American Society of Nephrology*. 2018;29(7):1849-1858. doi:10.1681/ASN.2017111179

151. Hurd TW, Otto EA, Mishima E, et al. Mutation of the Mg2+ transporter SLC41A1 results in a nephronophthisis-like phenotype. *Journal of the American Society of Nephrology*. 2013;24(6):967-977. doi:http://dx.doi.org/10.1681/ASN.2012101034

152. Zhou W, Otto EA, Cluckey A, et al. FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. *Nat Genet*. 2012;44(8):910-915. doi:10.1038/ng.2347

153. Bollée G, Dahan K, Flamant M, et al. Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. *Clinical Journal of the American Society of Nephrology*. 2011;6(10):2429-2438. doi:10.2215/CJN.01220211

154. Ekici AB, Hackenbeck T, Morinière V, et al. Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin. *Kidney Int*. 2014;86(3):589-599. doi:10.1038/ki.2014.72

155. Neumann H, Zauner I, Strahm B, et al. Late occurrence of cysts in autosomal dominant medullary cystic kidney disease. *Nephrology Dialysis Transplantation*. 2002;12(6):1242-1246. doi:10.1093/ndt/12.6.1242

156. Wolf M, Hildebrandt F. Nephronophthisis. *Pediatric Nephrology*. 2011;26(2):181-194. doi:10.1007/s00467-010-1585-z

157. König J, Kranz B, König S, et al. Phenotypic spectrum of children with nephronophthisis and related ciliopathies. *Clinical Journal of the American Society of Nephrology*. 2017;12(12):1974-1983. doi:10.2215/CJN.01280217

158. Dell KM, Morrison Hurley R, Guay-Woodford LM, et al. Design and implementation of the hepatorenal Fibrocystic Disease core center clinical Database: a centralized resource for characterizing autosomal recessive Polycystic Kidney Disease and Other hepatorenal Fibrocystic Diseases. 2017;5:80. doi:10.3389/fped.2017.00080

159. Guay-Woodford L. Autosomal recessive polycystic kidney disease: The prototype of the hepato-renal fibrocystic diseases. *J Pediatr Genet*. 2016;03(02):089-101. doi:10.3233/pge-14092

160. Reiter JF, Leroux MR. Genes and molecular pathways underpinning ciliopathies. *Nat Rev Mol Cell Biol*. 2017;18(9):533-547. doi:10.1038/nrm.2017.60

161. Bingham C, Ellard S, Van’t Hoff WG, et al. Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor-1β gene mutation. *Kidney Int*. 2003;63(5):1645-1651. doi:10.1046/j.1523-1755.2003.00903.x

162. Chan SC, Zhang Y, Shao A, et al. Mechanism of Fibrosis in HNF1B -Related Autosomal Dominant Tubulointerstitial Kidney Disease. *Journal of the American Society of Nephrology*. 2018;29(10):2493-2509. doi:10.1681/asn.2018040437

163. Casemayou A, Fournel A, Bagattin A, et al. Hepatocyte nuclear factor-1b controls mitochondrial respiration in renal tubular cells. *Journal of the American Society of Nephrology*. 2017;28(11):3205-3217. doi:10.1681/ASN.2016050508